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The introduction of the anticoagulant drug heparin nearly a century ago gave physicians 
the ability to precisely control blood clotting. Yet the difficulty in synthesizing heparin 
necessitates its extraction from animal tissue, which has led to serious issues with 
contamination (Liu, Zhang et al. 2009). Heparan sulfate (HS) is an analog of heparin found 
throughout animal cells which modulates many biological events. Improving heparin and 
exploring new HS-based drugs requires improved synthetic and analytic tools. We developed a 
method to link chemoenzymatically synthesized heparin fragments that display inhibition of the 
primary effector in the coagulation cascade, thrombin (factor IIa). Heparin facilitates the 
dimerization of factor IIa with its inhibitor antithrombin (AT). This interaction requires a minimum 
of a 19-mer (Xu, Pempe et al. 2012), with AT and IIa bound at opposite termini, separated by a 
“bridge” region.  The copper catalyzed azide-alkyne cycloaddition (CuAAC) was used to link AT 
and IIa binding fragments to prepare heparin mimetics. We examined IIa inhibition with a series 
of oligosaccharides ranging from 15- to 24-mers. Like contiguous heparin, the mimetics showed 
a size-dependent increase in anti-IIa activity. To further develop chemical tools for the analysis 
of HS, we sought to characterize the substrate specificity of K5 lyase A (KflA), a novel 
polysaccharide enzyme known to cleave HS. Heparin lyase enzymes are an integral part of the 
analysis of heparin and HS polysaccharides.  A series of structurally defined synthetic HS 
oligosaccharides was used to characterize the minimum size of a KflA substrate and to show 
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CHAPTER 1: BACKGROUND 
 Glycans are one of the major classes of biomolecules, and display richly varied forms 
and functions. Heparan sulfate (HS) is a glycan that influences fundamental biological 
processes in animals. Heparin is a specialized type of HS which has been a major anticoagulant 
drug for over 75 years (Linhardt 2003). Both are key members of a class of glycans known as 
glycosaminoglycans (GAGs), which are un-branched, acidic polysaccharides built from a 
repeating disaccharide consisting of a hexosamine linked to either a hexose or hexuronic acid. 
There are five types, all of which except hyaluronan are sulfated during biosynthesis by 
sulfotransferases that target specific positions on the disaccharide (Figure 1.1) (Sarrazin, 
Lamanna et al. 2011). Dermatan sulfate and HS/heparin are also subject to epimerization at the 
5-carbon of glucuronic acid (Figure 1.1). The multiple modifications of heparin/HS generate 
tremendous variability, and their biological functions and pharmacological potential are the 
subject of active exploration. This chapter will discuss the biological significance of HS and 






Figure 1.1. Sulfated glycosaminoglycans. Yellow squares indicate potential sulfation sites, blue circles 
show carbons that may be epimerized, and red represents the HS amino group which may be sulfated, 
acetylated, or in unsubstituted “free amine” form. Heparin and HS have the most possible modifications 
and 48 theoretically possible disaccharides (Esko and Selleck 2002) 
 
Introduction to HS and Heparin 
Heparin and HS share the same backbone polysaccharide, but are biosynthetically 
modified in distinctly different ways. Heparin has a significantly higher level of sulfation and 
epimerization. For example, in pigs,  89% of all heparin glucosamine residues are N-sulfated, 
compared to only 43% for HS (Lyon, Rushton et al. 2000). This trend is more pronounced for 2-
O- and 6-O-sulfation, with these positions about 90% sulfated in heparin, compared to only 20% 
of 2-O and 6-O-groups in HS (Lyon, Rushton et al. 2000). In general, an average heparin 
disaccharide contains about 2.6 sulfate groups, while HS contains 0.6 sulfates per disaccharide 
(Liu and Linhardt 2014). Heparin is also more homogenous, with its structure dominated by the 




heparin. (Linhardt, Cohen et al. 1989). Chains of HS, on the other hand, are built from diverse 
disaccharides, with low-sulfated disaccharides as major components. (Hileman, Smith et al. 
1997).  
A distinct feature of HS is a linear domain structure. There are highly sulfated heparin-
like “NS” domains, unmodified “NAc” domains, and “NAc/NS” domains with intermediate levels 
of sulfation flanking the NS domains (Figure 1.2) (Maccarana, Sakura et al. 1996). The average 
spacing between two NS domains is 16-18 disaccharides, and NAc regions span about 8-9 
sequential disaccharides (Maccarana, Sakura et al. 1996, Murphy, Merry et al. 2004). The 
NAc/NS domains are built from a repeating tetrasaccharide [GlcNAc-GlcA-GlcNS6S-IdoA], 
shown in Figure 1.2 (Murphy, Merry et al. 2004). Specific deviations from these rules have been 
identified. For example, isolated GlcNS and GlcNAc6S residues are found in NAc domains, and 
GlcNS residues in NS domains may lack 6-O-sulfation (Figure 1.2) (Maccarana, Sakura et al. 








Figure 1.2. Structures of heparin and heparin sulfate. Heparin contains high levels of the disaccharide 
GlcNS6S-IdoA2S, as well as variability to allow for sequences like the antithrombin (AT) binding site 
shown in the dashed box. Heparin is usually processed into free GAGs while HS chains remain linked to 
a core protein. A key feature of HS is domain organization. Highly sulfated NS domains are similar to 
heparin. NAc/NS domains are transition zones between unmodified NAc regions and NS domains. 
Variation in 6-O- and 3-O- sulfation occurs in NS domains, while NAc domains exhibit some N- and 6-O-
sulfation (Murphy, Merry et al. 2004) 
 
Proteoglycans 
HS is unique to animals, and in vertebrates it is found on the surfaces of essentially all 
cell types as well as throughout the extracellular matrix (Kraemer 1971, Hedman, Kurkinen et al. 
1979). HS, heparin and the other sulfated GAGs are synthesized with the reducing end of the 
polysaccharide in an O-linkage to specific serine residues of proteins. The covalently linked 
GAG-protein complex forms what is referred to as a proteoglycan, and the core proteins are 
limited to a few specific families (Bernfield, Gotte et al. 1999).  
 Syndecans and glypicans are the major cell surface proteoglycans, and are anchored to 
the cell membrane through either an integral transmembrane domain or a 




syndecans and glypicans range from 31-69 kDa, and may be linked to from 1-3 HS chains. 
There are also HS proteoglycans in the extracelluar matrix, the major ones being perlecan (400 
kD, 1-4 chains) and agrin (212 kD, 2-3 chains) (Sarrazin, Lamanna et al. 2011). There are four 
syndecans, six glypicans (Consortium 2015), and multiple splice forms of perlecan and agrin 
(Iozzo 2001). Other variations in proteoglycans including HS chain length, number of chains, 
different types of sulfation/epimerization, and combinations with other GAGs results in huge 
variety among HS proteoglycans (Sarrazin, Lamanna et al. 2011).  
 Heparin is not as widespread as HS in vivo and is restricted to specific types of immune 
cells. It is biosynthesized on a single core protein, serglycin, an 18 kDa protein with a serine rich 
sequence containing eight potential linkage sites (Carlsson and Kjellen 2012). Unlike HS, 
heparin is often cleaved from its core protein and in free GAG form. Following biosynthesis, 
heparin chains may be processed by the endo-glucuronidase heparanase, with the extent of 
cleavage varying for different tissues (Gong, Jemth et al. 2003). Heparin from rat skin and 
peritoneal tissue, for example, has a molecular weight of 60-100 kDa, which is about five times 






Figure 1.3. Functions of HS proteoglycans. A. Binding to HS by growth factors and other signaling 
proteins regulates their diffusion and protects from degradation. (Bishop, Schuksz et al. 2007). B. HS acts 
as a co-receptor and facilitates growth factor-receptor binding (Bishop, Schuksz et al. 2007) C. 
Heparanase (HPSE) cleavage frees sequestered proteins and leads to altered signaling  (Fux, Ilan et al. 
2009) D. Sulfatases (Sulf) cleave specific sulfates and modulate HS affinity (Ai, Do et al. 2006). E. 
Interaction with the extracellular matrix (ECM) influence cell adhesion (Bishop, Schuksz et al. 2007). 
Pathogens recognize HS sequences during cell entry (Liu and Thorp 2002). 
 
The HS chains in proteoglycans range from 20-250 disaccharides (Xu and Esko 2014), 
making them prominent cell surface structures, and the sulfate rich regions are well suited for 
interaction with basic residues on proteins. The HS proteoglycans interact with a large list of 
proteins including growth factors, morphogens, chemokines, cytokines, extracellular matrix 
molecules, and members of the coagulation and complement systems (Ori, Wilkinson et al. 
2008). Over 200 HS binding proteins were identified in a recent literature review (Ori, Wilkinson 
et al. 2011). Through their many interactions, HS proteoglycans influences processes including 
development, cell adhesion, blood hemostasis, tumor metastasis, angiogenesis, inflammation, 
and cell entry of pathogens (Bishop, Schuksz et al. 2007).  
HS proteoglycans are heavily involved in cell growth and differentiation. During 




coordinated fashion, which is in large part mediated by their interactions with HS proteoglycans. 
The HS functions to keep the growth factors close to the cell and limits diffusion into the 
extracellular matrix, as well as targets them to specific cells (Figure 1.3) (Yan and Lin 2009). 
The protein binding interactions often show some level of specificity to the monosaccharide 
sequences of HS. The modifications of HS are not homogenous throughout an organism, 
instead, different tissues show unique “signatures” in terms of their level of epimerization and 
different types of sulfation (Turnbull, Powell et al. 2001). In fact, for members of the same 
species, HS modifications show more variation between types of tissues in one individual than 
between the same tissue in different individuals (Warda, Toida et al. 2006). Furthermore, the 
modifications of HS change in time, as seen with HS-specific antibodies that show changes in 
the levels of various epitopes during development (Jenniskens, Hafmans et al. 2002). These 
changes have been correlated with changes in HS affinity for different growth factors over time 
(Allen and Rapraeger 2003) 
Beyond simply sequestering proteins, HS proteoglycans are often an integral part of 
their signaling. A well-studied example is the interaction between HS, fibroblast growth factors 
(FGFs), and fibroblast growth factor receptors (FGFRs) a tyrosine kinase type receptor. The HS 
acts as a co-receptor by binding both FGF and the receptor, acting as a molecular scaffold 
aiding assembly of the complex (Figure 1.3) (Rapraeger, Krufka et al. 1991). In the structure of 
a ternary complex of a heparin oligosaccharide, FGF-2, and FGFR-1, the receptor subunits and 
a growth factor dimer form a complex with two heparin hexasaccharides positioned in a basic 
cleft in the center (Schlessinger, Plotnikov et al. 2000). Although the structure crystallized with 
two octasaccharides in the cleft, in vivo studies show a dodecasaccharide is required for FGFR-
1 signaling (Guimond, Maccarana et al. 1993, Schlessinger, Plotnikov et al. 2000). Another 
example is the HS-interacting growth factor vascular endothelial growth factor 165 (VEGF165), 




HS, but it is potentiated by it (Bernfield, Gotte et al. 1999). Sulfate-rich sections of HS increase 
VEGF165 signaling by aiding in dimerization of the growth factors (Robinson, Mulloy et al. 2006).  
HS proteoglycans also play important roles in cell adhesion. Focal adhesions are 
assemblies in the lipid membrane that interact with the extracellular matrix and transfer signals 
on the local environment into the cell. Cells deficient in GAGs display a different adhesive 
phenotype than the wild type when grown on a fibronectin substrate (LeBaron, Esko et al. 1988)  
HS chains on syndecan-4 make contact with HS-binding HepII domains of fibronectin in the 
extracellular matrix (Figure 1.3) which aids in the clustering of syndecan-4 into focal adhesion 
complexes (Woods, Longley et al. 2000) and signals changes to the actin cytoskeleton (Gopal, 
Bober et al. 2010). 
Outside the cell, the sulfation and epimerization patterns of HS chains can be modified 
by secreted enzymes. The two extracellular endosulfatases, hSulf-1 and hSulf-2, both remodel 
HS sulfation, specifically acting on 6-O-sulfate groups (Ai, Do et al. 2006) which can lead to up- 
and down-regulation of the effects of growth factors including Wnt (Dhoot, Gustafsson et al. 
2001), FGF-2, VEGF165, and hepatocyte growth factor (Figure 1.3) (Billings and Pacifici 2015). 
With FGF-2, 6-O-sulfated HS is required for the full assembly and subsequent signaling of the 
FGF-receptor complex (Guimond, Maccarana et al. 1993, Rusnati, Coltrini et al. 1994) When 
the activity of Hsulf-1 is repressed, it leads to increased proliferative effects by FGF-2 in ovarian 
cancer cells, which can be reversed by re-expression of Hsulf-1 (Lai, Chien et al. 2003, Narita, 
Staub et al. 2006). 
  Heparanase is an HS-cleaving enzyme that has been implicated in cancer (Mahtouk, 
Hose et al. 2007). Increased expression of heparanase is correlated with higher chance of 
metastasis in tumor cells (Hulett, Freeman et al. 1999, Mahtouk, Hose et al. 2007). Heparanase 




metastasis (Hulett, Freeman et al. 1999), as well as releasing bound signaling proteins which 
can aid in processes like tumor angiogenesis (Figure 1.3) (Hammond, Khurana et al. 2014). 
Both sulfatases and heparanase are attractive drug targets for cancer because of their effect on 
the tumor microenvironment (Hammond, Khurana et al. 2014). For example, the heparanase 
inhibitor PI-88 is a sulfated mannopentaose heparin mimetic (Khachigian and Parish 2004) that 
proceeded to phase III clinical trials (although they were terminated) (Gnoni, Santini et al. 2015). 
Other disorders involving HS proteoglycans include viral infection and genetic disorders. 
Numerous viruses exploit the abundant HS on animal cells including herpes simplex virus 1 
(HSV-1) (Shieh, Wudunn et al. 1992), dengue virus (Chen, Maguire et al. 1997), and human 
immunodeficiency virus (HIV) (Cladera, Martin et al. 2001) (Figure 1.3). Binding to HS 
sequences occurs in the initial stages of viral entry in concert with binding to other cell surface 
proteins (Liu and Thorp 2002). These interactions have been shown to be quite specific in some 
cases, such as HSV-1 binding to a rare 3-O-sulfated HS sequence (Shukla, Liu et al. 1999). 
There are also genetic disorders. Hereditary multiple exostoses is characterized by painful bone 
deformities and outgrowths (or exostoses) caused by loss of function in one or more of the 
genes responsible for HS polymerization, exostosin 1 and exostosin 2 (EXT1, EXT2), and 
affects about 1-2 in every 100,000 people (Li and Kusche-Gullberg 2016). This parallels EXT1/2 
deficiencies in mice, where one-third of heterozygous EXT2 mutants displayed bone exostoses 
as well as irregularities in cartilage formation (Stickens, Zak et al. 2005). Proteoglycans also 
function in the nervous system, influencing processes including synapse formation and axon 
guidance (Smith, Coulson-Thomas et al. 2015).   
Unlike HS, heparin is restricted to mast cells in mucosal and epithelial tissue (Krystel-
Whittemore, Dileepan et al. 2016). The cytoplasm of mast cells contains about 50-200 
“granules”, membrane bound compartments packed with heparin, histamine, serotonin, and 




degranulation, which releases the contents of granules into the cells local environment and 
increases vascular permeability and inflammation (Theoharides, Valent et al. 2015).  Based on 
its pharmaceutical effects, heparin was initially thought to function as an anticoagulant, but this 
changed after finding that heparin is restricted to mast cells. Heparin functions are still being 
fully fleshed out, although it is known to be required for correctly formed mast cell granules 
(Forsberg, Pejler et al. 1999), with the highly anionic chains probably aiding with packaging of 
the basic histamines (Kolset, Prydz et al. 2004). Heparin also assists histamine in increasing 
vascular permeability by activating pathways leading to increased amounts of the vasodilator 
bradykinin (Oschatz, Maas et al. 2011).  
Structure of heparin and HS 
The basic disaccharide building block of heparin and HS is [-4)-α-D-GlcA-(14)-β-D-
GlcNAc-(1]. GlcA is often epimerized to IdoA which gives the disaccharide [-4)-β-L-IdoA-
(14)-β-D-GlcNAc-(1]. The epimerization of GlcA to IdoA is an important structural 
modification of heparin and HS. Iduronic acid, especially IdoA2S, is much more conformationally 
flexible than glucuronic acid, glucosamine, and their sulfated analogues, which are stable in the 
4C1 chair conformation. On the other hand, IdoA and IdoA2S convert between the 2S0 skew boat 
and the 1C4 chair conformers with an equilibrium ratio that fluctuates around 1:1 (Rabenstein 
2002), and a small fraction of IdoA, usually less than 10%, can be found in the 4C1 chair (Figure 
1.4) (Ferro, Provasoli et al. 1990).  The skew-boat and chair forms interconvert on a μs time-
scale, allowing the use of NMR 3JH-H coupling constants to determine their ratios (Hsieh, Thieker 
et al. 2016). The sulfation state of neighboring residues has a significant effect on the 2S0 : 1C4 
ratio. Increasing sulfation causes IdoA2S to adopt the 2S0 form while having the inverse effect 
on IdoA, which tends toward 1C4 (Hsieh, Thieker et al. 2016). The ratios are dependent on 
several other factors, including the solvent environment, protein-binding, and proximity to the 




The conformational flux of iduronic residues increase the protein binding capacity of 
heparin and HS by increasing the possible arrangements of sulfate groups (Capila and Linhardt 
2002). Protein binding can lock iduronic acids into a single conformation, selecting a specific 
arrangement of binding groups from the equilibrium mixture.  One example is the seen in the 
crystal structure of basic fibroblast growth factor receptor bound to a heparin fragment. One of 
the two central IdoA2S residues of the hexasaccharide is in the 2S0 form and the other is 1C4, 
with both making contacts with the protein (Faham, Hileman et al. 1996).  
 
Figure 1.4. HS and heparin monosaccharides and their conformers. GlcNAc, GlcA and their sulfated 
analogs are stable in the 4C1 conformation. Using 4C1 as an example, this notation denotes the 0, 2, 3, 
and 5 atoms of the ring lie in a plane, and the 4 and 1 carbons are above and below the plane, 
respectively. IdoA and IdoA2S exist in equilibrium between the 1C4 chair and the 2S0 skew-boat forms, with 
a small contribution from the 4C1 form usually only observed with IdoA. 
 
The IdoA2S conformation is also crucial in binding of heparin to antithrombin (AT), a 
serine protease inhibitor that inactivates members of the coagulation cascade and is key to the 
anticoagulant activity of heparin (Linhardt 2003). Binding to a specific pentasaccharide 
sequence, which contains an IdoA2S in the second position from the reducing end, induces 
conformational changes in AT.  This greatly enhances its affinity to its target coagulation 
cascade proteases (Jin, Abrahams et al. 1997). A series of synthetic pentasaccharides with the 




coagulation factor Xa was dependent on its binding the 2S0  conformer. The 2S0  locked 
pentasaccharide was 89% as active as that of the non-locked control, while the 1C4 form was 
only 4% as active. (Jin, Abrahams et al. 1997).  
The major approaches for the study of the molecular structure of heparin and HS at the 
oligosaccharide level are computational modeling based on NMR-derived constraints, and 
analysis of heparin-protein crystallographic complexes (Mulloy and Forster 2000). A crucial 
factor is the determination of the rotational angle of the glycosidic bonds. In carbohydrates the 
dihedral rotation of the glycosidic bond is described by the phi () and psi () angles, defined by 
H1-O-C1’-H1’ and C1’-O-C1-H1, respectively (Figure 1.5) (Rabenstein 2002). Atoms marked by 
a prime symbol correspond to the adjacent residue toward the reducing end (Sinnot 2007). 
Mulloy et al., estimated the  and  angles of heparin using 1H-1H through-space coupling 
(nuclear Overhauser effect, or NOE) between protons on adjacent residues  (Mulloy, Forster et 
al. 1993). The NOE estimation of the distances between protons was then used as the basis of 
constraints for minimization of a dodecasaccharide in an MM2 force field. This was done with 
two dodecasaccharide models of heparin, one with all IdoA2S monosaccharides in the1C4 
conformation and one with all in 2S0 form, as shown in Figure 1.4. Intramolecular repulsions 
from the anionic groups of heparin tend to give it a rod-like structure. It has a helical form with 4 
residues per turn, and a length of 4.0-4.5 nm per residue (Mulloy, Forster et al. 1993). Although 
most structural studies have focused on heparin because of its use as a drug and ready 
availability, recent work shows HS appears to have a more bent and elongated overall 






Figure 1.5. HS/Heparin dihedral angles.  The colored quadrants show the signs of the  and  values 
for the two types of linkages. Both solution state and protein-bound structures have similar values (Mulloy 
and Forster 2000). 
 
Heparin Protein Interactions 
The first attempts to generalize the characteristics of heparin binding sites in proteins 
were by Cardin and Weintraub, who formulated the idea of linear consensus sequences 
(Hileman, Fromm et al. 1998). They proposed heparin binding sequences of the form [-X-B-B-X-
B-X-] and [-X-B-B-B-X-X-B-X-], where B represents a basic amino acid and X is hydropathic 
(Cardin and Weintraub 1989). In Cardin and Weintraub’s model, basic groups are oriented 
toward one side of a beta strand or alpha helix, optimally positioned for electrostatic interactions 
with sulfate groups on one face of a heparin chain (Cardin and Weintraub 1989).  Later Margalit 
et al examined solved crystallographic structures and described binding sequences flanked by 
basic residues 20 Å apart (Margalit, Fischer et al. 1993), which closely matches with the 17.5 Å 
separation between clusters of sulfate groups on heparin (Zhou, Hook et al. 1992). This model 
differs from the Cardin-Weintraub model in that the basic residues are on different sides of 
structural elements of the protein, with side chains oriented at 180˚ to one another, which forces 
“coiling” of the heparin chain around the protein. This provides a possible mechanism for 
heparin binding to induce conformational changes in a protein (Margalit, Fischer et al. 1993). 
After the accumulation of more heparin-protein crystal structures, it’s clear that there are also 
many binding sites that are not contiguous in the protein’s primary structure and are a result of 






Figure 1.6. Solution structure of heparin. A. The superposition of two dodecasaccharides composed of 
repeating IdoA2S-GlcNS6S. The green structure contains all IdoA2S in 2S0 form; in purple they are 1C4. 
In spite of the different conformations they superimpose with an RMSD of 2.15 Å (Schrödinger 2016). The 
conformational change has little effect on the orientation of the glycosidic bonds, although the 2-O-sulfate 
groups show an average displacement of 4.1 Å. B and C. shows the individual chains, as well as the view 
down the long axis with the reducing end into the page. D. A map of the electrostatic potential (red shows 
negative charge, blue is positive) reveals clusters of negative charge. (PDB 1hpn).  
 
Analysis of HS and heparin disaccharide composition 
The composition of heparin and HS has traditionally been analyzed by both enzymatic 




heparinus (Casu and Lindahl 2001). Each has different substrate specificities, which are largely 
dependent on the sulfation/epimerization state of the hexuronic acid at the cleavage site (Desai, 
Wang et al. 1993). As shown in Figure 1.7, all the heparin lyases cleave between glucosamine 
and hexuronic acid, and incubation with all three will tend to degrade heparin or HS into its 
constituent disaccharides (Casu and Lindahl 2001). Another HS-active lyase is the tailspike 
protein from the K5A bacteriophage, which is specific for unmodified heparin/HS (Rek, 
Thompson et al. 2007). Although the lyases are valuable for analysis and avoid the harsher 
conditions of chemical degradation, a disadvantage is the loss of information on the 
configuration at the C5 position of hexuronic acid. An alternative is depolymerization through 
reductive deamination, which, as shown in Figure 1.7, preserves the epimerization state of the 
hexuronic acid. At pH 1.5, treatment with nitrous acid results in cleavage between N-sulfated 
glucosamine and hexuronic acid. Prior treatment of the polysaccharide with hydrazine is often 
used to deacetylate N-acetyl groups before nitrous acid treatment at pH 3.0, resulting in 
cleavage of both N-sulfated and unsubstituted “free-amine” glucosamines (Casu and Lindahl 
2001).  
Analysis of lyase degraded polysaccharides is usually done with HPLC. Peaks can be 
identified by comparing elution times to commercially available disaccharide standards or 
desalted and analyzed by mass spectrometry. The presence of the ∆4,5-unsaturated bond in the 
lyase cleaved products allows them to be detected with a UV-absorbance of 232 nm (Jones, 
Beni et al. 2011). Because samples of HS are often limited, more sensitive methods have been 
developed, including labeling with fluorophores like BODIPY-hydrazide, which gives a 2,000-fold 
increase in sensitivity (Skidmore, Guimond et al. 2010). Products prepared through nitrous acid 






Figure 1.7. Analysis of heparin/HS disaccharides. A. Cleavage with a lyase (heparin lyase I, II, and III 
or K5 lyase) proceeds through a β-elimination and cleaves between glucosamine and a hexuronic acid. 
The example shows the unmodified disaccharide, but the lyases exhibit different specificities. Information 
on the orientation of the 5-carbon of hexuronic acid is lost after cleavage. B. Degradation by nitrous acid, 
cleaves between N-sulfated glucosamine and hexuronic acid and generates a 2,5-anhydromannose 
residue on the reducing end. The example uses GlcNS-GlcA, but any N-sulfated disaccharide will be 
cleaved and the O-sulfation and 5-carbon configuration will be preserved.  
 
Biosynthesis of HS and heparin 
 Heparin and HS synthesis takes place in the golgi and is initiated with the assembly of a 
tetrasaccharide on a specific serine on the core protein (Kreuger and Kjellen 2012). Xylose is 
added first, by one of two xylose transferases, XT1 or XT2 (Kreuger and Kjellen 2012). Two 
galactose residues are added next, first by galactosyltransferase 1 (GalTI), then the second 
monosaccharide by galactosyltransferase II (GalTII). A glucuronic acid is then added by 
glucuronosyltransferase I (GlcATI)  (Esko and Selleck 2002). At this point, the tetrasaccharide 
linker [-β-D-GlcA-(13)-β-D-Gal-(13)-β-D-Gal-(14)-β-D-Xyl-] has been assembled (Figure 
1.7). One step remains before chain elongation can begin. The tetrasaccharide linker for HS 
and chondroitin sulfate chains is identical, and which GAG will be added depends on whether a 




The α-N-acetylglucosaminyltransferase EXTL3 add GlcNAc and distinguishes HS linkage sites 
through clusters of acidic amino acids near the reducing end serine (Esko and Zhang 1996).  
 Polymerization is carried out by the heterodimer HS copolymerase, consisting of 
exostosins EXT1 and EXT2 (McCormick, Duncan et al. 2000). HS copolymerase requires both 
EXT1 and 2 to function (Senay, Lind et al. 2000). Yeast expressed EXT1 and EXT2 do not 
exhibit glycosyltransferase activity individually, or mixed in vitro, but need to be co-expressed for 
proper transfer of GlcNAc and GlcA (Senay, Lind et al. 2000).  
HS copolymerase, along with the array of glycosyltransferases involved in chain 
initiation, requires uridine diphosphate (UDP) sugars as cosubstrates for transfer of a 
monosaccharide to the nonreducing end of a carbohydrate chain (Figure 1.7) (Esko and Selleck 
2002). The UDP-sugars are transferred from the cytosol into the golgi lumen through specific 
nucleotide sugar transporters which also remove uridine monophosphate (UMP) reaction 
products (Hirschberg, Robbins et al. 1998). Regulation of UDP-sugar availability has been 






Figure 1.8. HS and heparin biosynthesis: AT-binding pentasaccharide sequence. 1) Synthesis 
begins with assembly of a tetrasaccharide. 2) Several GAG types can be added to the tetrasacharide; but 
EXTL3 adds a GlcNAc to initiate HS/heparin synthesis (Sarrazin, Lamanna et al. 2011). 3) Elongation by 
the EXT1/EXT2 heterodimer requires UDP-sugars. HS chains range from 20-250 disaccharides  (Xu and 
Esko 2014) 4) NDST carries out both N-deacetylation and N-sulfation.  GlcNS residues form the basis of 
most further enzyme modifications 5-6) Hsepi epimerizes GlcA to IdoA, both of which are acted on by 2-
OST, with preference to IdoA . 7) 6-OST sulfates both GlcNS and GlcNAc. 8). 3-O-sulfation is only found 
in about one-third of heparin chains but is important for anticoagulant function (Linhardt 2003). Though 









Modification of the N-acetyl heparosan chain begins with N-deacetylase/N-
sulfotransferase (NDST). It is a bifunctional enzyme that converts GlcNAc to GlcNS through the 
action of two domains: a deacetylase domain which cleaves the GlcNAc amide bond, and a 
sulfotransferase that sulfates GlcNH2 to give GlcNS (Mandon, Kempner et al. 1994). NDST is 
instrumental in forming the highly sulfated NS domains of HS due to the specificity for N-
sulfated residues in Hsepi (Sheng, Xu et al. 2012), 2-O-sulfotransferase (Liu, Sheng et al. 
2014), and 3-O-sulfotransferase (Liu, Moon et al. 2012). There are four NDST isoforms in 
humans (Table 1.1), and NDST-1 is the most highly expressed and widely distributed in 
different tissues (Dou, Xu et al. 2015). Recent evidence indicates cooperativity between the 
functional domains of NDST-1 in establishing sulfation patterns. Full length NDST-1 formed 
contiguous N-sulfated sequences of mostly tetra- to deca-saccharide size, while a mixture of the 
individual domains yielded mostly isolated GlcNS residues (Dou, Xu et al. 2015). Genetic 
evidence suggests that isoform 1 is key in the synthesis of HS, while NDST-2 is required for the 
synthesis of heparin. NDST-2-/- mice are viable and fertile, but exhibit abnormal mast cells 
(Forsberg, Pejler et al. 1999), while NDST-1-/- mice showed respiratory distress followed by 
neonatal death (Fan, Xiao et al. 2000).  
Sulfotransferase general structure and mechanism 
The sulfotransferase domain of NDST-1 with bound PAP was the first HS 
sulfotransferase with a solved crystallographic structure (Kakuta, Sueyoshi et al. 1999). In 
NDST-1 the sulfate group of PAPS oriented toward a hydrophilic cleft on the enzyme surface  
(Kakuta, Sueyoshi et al. 1999). The location of the substrate binding cleft was confirmed with 
the ternary structure of 3-OST-3 bound to PAP and a heparin tetrasaccharide (Moon, Edavettal 




similar overall fold (Liu, Moon et al. 2012). The mechanism involves SN2 attack on the PAPS 
sulfate group by substrate amine or alcohol (Moon, Edavettal et al. 2004). The HS modifying 
enzymes are bound to the Golgi membrane through an approximately 20 amino acid N-terminal 
transmembrane domain, with the C-terminal catalytic domain extending into the Golgi lumen 
(with the exception of 3-OST1 which lacks a transmembrane domain) (Kusche-Gullberg and 
Kjellen 2003). 
C5-epimerase and 2-O-sulfotransferase 
The conversion of GlcA to IdoA is carried out by D-glucuronyl C5-epimerase (Hsepi). 
The target trisaccharide of Hsepi is [GlcNS-GlcA-GlcNS/Ac] allowing for the synthesis of NS and 
NS/NAc domains (Sheng, Xu et al. 2012). Epimerization at the C5 position of the hexuronic acid 
involves a carbanion intermediate (Qin, Ke et al. 2015) and appears to be reversible in vitro 
with specific substrates (Sheng, Xu et al. 2012). Hsepi has been shown to associate with 2-O-
sulfotransferase both in vivo and in vitro (Pinhal, Smith et al. 2001, Prechoux, Halimi et al. 2015, 
Qin, Ke et al. 2015). Because 2-O-sulfated hexuronic acids are not a substrate for Hsepi 
association between the two enzymes may help to lock a specific epimer into place and drive 
the synthesis forward, (Hagner-McWhirter, Li et al. 2004). Both de-O-sulfated heparin [GlcNS-
IdoA]n and N-sulfated heparosan [GlcNS-GlcA]n are substrates for 2-OST, although the five-fold 
lower KM for de-O-sulfated heparin reflects a preference for IdoA (Rong, Habuchi et al. 2001). 
2OST product inhibition 
 One means of altering the rate of HS synthesis may be product inhibition (van den Born, 
Pikas et al. 2003). E. Coli expressed 2OST exhibits strong product inhibition by heparin In vitro, 
however, this was markedly reduced with P. Pastoris (yeast) expressed 2-OST, increasing the 
IC50 of heparin by a factor of 40 (Zhou, O'Leary et al. 2012) Analysis of the sequence for N-




probability of glycosylation of over 50% by comparison with known N-glycosylated sequences 
by NetNglyc (Blom, Sicheritz-Pontén et al. 2004). When these sites were mapped to the  crystal 
structure of 2-OST and PAP (PDB 3F5F), residue N108 was in close proximity to the binding 
cleft (Zhou, O'Leary et al. 2012). Two mutants were expressed (N108A and N127A), and mutant 
N108A was highly sensitive to product inhibition. The heparin IC50 for the P. Pastoris N108A 
mutant was reduced 2000-fold, while the N127A mutant only exhibited a 2-fold reduction in IC50. 
More recent work has shown both N-glycosylated and non-N-glycosylated forms of 2-OST bind 
to downstream products of HS synthesis, with substrates exhibiting tighter binding with 
increasing sulfation, and higher overall affinity is observed for the N-glycosylated enzyme 
(Thieker, Xu et al. 2018). Aided by a crystal structure showing a hexasaccaride bound to 2-OST, 
mutagenesis and molecular modeling were employed to show non-productive binding by 6-O-
sulfated HS resulted from occupation of the PAPS binding site by 6-O-sulfate groups (Thieker, 
Xu et al. 2018) .   
 
Figure 1.9. Close proximity of N-glycosylation to HS binding cleft in 2-OST. The light pink colored 
structure is the substrate in the 2OST binding cleft. In green is an N-glycan core-pentasaccharide linked 






6-O-sulfotransferase and 3-O-sulfotransferase  
 While Hsepi and 2-OST each only exhibit one isoform in humans, there are three 
isoforms of 6-OST, and seven isoforms of 3-OST (Figure 1.8). The 6-OST and 3-OST enzymes 
carry out the final stage of HS biosynthetic modifications (Zhang, Beeler et al. 2001). All the 
isoforms of 6-OST sulfate on the C6 position of GlcNS, GlcNAc, and GlcNS3S residues 
(Smeds, Habuchi et al. 2003)  All 6-OSTs also appear to sulfate [GlcNS-GlcA] and [GlcNS-IdoA] 
polysaccharides, both with and without 2-O-sulfation (Smeds, Habuchi et al. 2003). However the 
precise differences between the specificity of the 6-OST isoforms is currently unknown. 
Experiments with pure substrates and obtaining one or more crystal structures should yield 
further insight.  
Sulfation at the C3 position of glucosamine by 3-OST is the most rare biosynthetic 
modification of HS and heparin (Thacker, Xu et al. 2014). In spite of its rarity 3-OST plays an 
important role in processes including anticoagulation and viral pathogenesis. The isoforms of 3-
OST can be classed in two categories: AT-type 3-OST sulfates the AT-binding site in heparin 
and HS, and the gD-type which adds a key sulfate in the HS sequence bound by the gD 
envelope protein of herpes simplex virus 1 (HSV-1) (Lawrence, Yabe et al. 2007). The primary 
AT-type isoform 3-OST-1 acts on [GlcA-GlcNS±6S] disaccharides (Figure 1.7), while the 
primary gD-type 3-OST-3 acts on [IdoA2S-GlcNH2±6S], and 3-OST-5 can sulfate both 






 Figure 1.10. Human HS sulfotransferases phylogenetic tree. The length of the grey bars corresponds 
to sequence similarity, shorter bars indicate greater similarity. Colored lines are for easier visualization of 
sulfotransferase groups. Multiple sequence alignment was performed with MUSCLE (MUltiple Sequence 
Comparison by Log-Expectation). (Edgar 2004) The unrooted phylogenetic tree was constructed with the 
Clustal-W2 Phylogeny web server. (McWilliam, Li et al. 2013). Sequences are verified entries from the 
Uniprot database (Consortium 2015).  
 
The molecular mechanism of heparin 
The interaction of heparin with AT is key to its pharmaceutical activity. Heparin enhances 
the inhibitory activity of antithrombin, which in turn leads to reduced generation of fibrin through 
the coagulation cascade.  In the coagulation cascade, a series of zymogens cleave and activate 
one another, resulting in the activation of thrombin, or factor IIa, one of the major effectors of 
coagulation (Figure 1.11). Damage to the vasculature releases tissue factor which initiates the 
cascade by forming a complex with factor VII (known as the extrinsic pathway). This leads to the 
activation of factor Xa, which in turn activates IIa. Factor IIa cleaves fibrinogen to yield fibrin, 
which self-associates to form the major protein component of thrombi (Mackman 2008). Factor 




initiation, the intrinsic pathway, occurs through biochemical signaling in plasma and entails 
multiple feedback loops, with several members interacting with factor IIa (Figure 1.11) 
 
Figure 1.11. The coagulation cascade (Mackman 2008). A series of zymogen proteases sequentially 
activate one another, resulting in factor IIa (or thrombin) generating the clot component fibrin. A complex 
of tissue factor and VII initiates the cascade (red squares, the extrinsic pathway) while the intrinsic 
pathway (grey) activates through signals in plasma and responds to feedback, including from factor IIa 
(green arrows). (Tanaka, Key et al. 2009). The protease inhibitor AT is activated by heparin and its 
derivatives. Shorter chains only inhibit Xa. Warfarin is another classical inhibitor of the cascade, and 
targets multiple clotting factors. Hirudin is a natural peptide that directly targets IIa, similar to synthetic 
small molecule direct thrombin inhibitors.  




 The coagulation cascade is down-regulated by two serine protease inhibitors, or serpins: 
antithrombin (AT) and heparin cofactor II. Of these two, AT is the most physiologically relevant 
and exists in a latent form in plasma at 2.3 µM (Gray, Hogwood et al. 2012). Antithrombin 
primarily targets factors Xa and IIa for inhibition. Heparin binding to AT induces it into an active 
form, and increases its rate of inhibition by several orders of magnitude.  
Activated heparin-bound AT functions by forming a 1:1 complex with its target protease 
where the “reactive site loop” (RSL) projects outward from AT and into the active site of the 
protease (Olson, Richard et al. 2010). The AT employs the RSL for a suicide-substrate type 
mechanism whereby the catalytic serine of the protease attacks the RSL at the “P1” amide 
bond. (Olson, Richard et al. 2010). The formation of the covalent acyl-intermediate triggers the 
newly cleaved loop to fold back and insert into a beta sheet in AT, pulling the protease with it, 
which induces it into a disordered state unable to complete the catalytic cycle. (Huntington, 
Read et al. 2000).  
The total synthesis of the AT-binding pentasaccharide provided a powerful tool for 
unraveling the mechanism of AT. Kinetic studies revealed that at 99% saturation by heparin 
polysaccharide, the rate of AT inhibition of Xa increases 580 times, and the rate of IIa inhibition 
increases 4300 times. However, the pentasaccharide causes a 270-fold rate increase for Xa, 
but only 1.7-fold for IIa (Olson, Bjork et al. 1992). Clearly, the pentasaccharide causes 
essentially no inhibition of IIa, but is effective for Xa.  This leads to several questions pertinent to 
the design of heparin-based drugs. What is the basis of activation of AT by heparin? Secondly, 






Figure 1.12. AT-binding pentsaccharide. Panels A and B show the AT-binding pentasaccharide. The R 
group is usually an acetyl group but can be sulfate, as in the bovine AT-site. Panel B is a model of the 
pentasaccharide in solution (http://glycam.org; Woods Group. 2005-2016 GLYCAM Web. Complex 
Carbohydrate Research Center, University of Georgia, Athens, GA) The box shows heparin catalyzed 
inhibition of factor Xa and IIa. Binding of AT to heparin induces its active conformation (step C2 and D2). 
In C3, AT makes tight contact with Xa, allowing the pentasaccharide alone to inhibit Xa. The interaction 
between IIa and AT is weak, requiring heparin to bridge the two proteins. Both AT and IIa interact with the 
heparin chain (step D2), and IIa “slides” into activated, bound AT (Linhardt 2003).   
 
Effect of heparin molecular size on anticoagulant activity 
Binding of the AT-specific region of heparin to AT takes place through an induced-fit type 
mechanism (Olson, Richard et al. 2010). Rearrangements at the pentasaccharide binding site 
results in lengthening of the major D-helix, and the extrusion of several RSL “hinge” residues 
from a β-sheet in AT. This brings the RSL into position for insertion into the protease active site 
(Olson, Richard et al. 2010).  
A series of mutagenic and crystallographic studies have addressed the different 
responses to chain length in IIa and Xa. Additionally, factor IXa is also inhibited by AT, and like 
Xa, only requires the pentasaccharide for inhibition (Johnson, Langdown et al. 2010). Initial 




IIa active site still did not allow the pentasaccharide-AT complex to inhibit IIa, though the mutant 
AT-pentasaccharide remained capable of inhibiting Xa (Chuang, Swanson et al. 2001). Instead, 
the difference is due to a pocket of residues on AT that binds a highly conserved Arg 150 
residue found on both Xa and IXa, but not IIa (Olson, Richard et al. 2010). In fact, mutation of 
key residues of the AT pocket (Tyr 253 and Glu 255) severely diminish AT inhibition of Xa and 
IXa, but leaves IIa inhibition virtually unaffected (Izaguirre and Olson 2006). Combined with the 
fact that heparin fragments must be at least 19 residues to elicit anti-IIa activity (Xu, Pempe et 
al. 2012), the conclusion is that longer heparin fragments are required to act as a bridge or 
scaffold to facilitate the interaction between IIa and AT. This is clearly shown with the crystal 
structures of an AT-Xa-pentasaccharide complex and an AT-IIa-hexadecasaccharide heparin 






Figure 1.13. AT-heparin mimetic complexes of Xa and IIa. Top structure shows Xa with 
pentasaccharide bound AT. The green sphere amino acids of AT form a binding pocket for R150 of Xa 
(PDB 2GD4). In the IIa complex, the same AT residues are shown, but none of the three nearest residues 
of IIa occupy the pocket, which is occupied by the light green solution molecule  (PDB 1TB6). (prepared 
with Schrodinger Maestro 2016 and Pymol).  
 
 The bridging mechanism of heparin seen in the AT-IIa interaction is a common theme 
among HS and its protein binding partners (Xu and Esko 2014). Facilitating protein-protein 
interactions is seen as a primary role of HS: “An attractive hypothesis for the diverse roles of cell 




Gotte et al. 1999) Several examples were mentioned above, like the dimerization of VEGF165 
growth factors (Robinson, Mulloy et al. 2006) and the FGF1-FGFR2-heparin interaction 
(Pellegrini, Burke et al. 2000). Other examples include dimerization of growth factors Hedgehog 
(Whalen, Malinauskas et al. 2013) and RANTES(9-68) (Vives, Sadir et al. 2002), protein C 
inhibitor and IIa, protein C inhibitor and activated protein C, FGF2 and FGFR1 (Xu and Esko 
2014) .   
Historical development of heparin 
 Heparin is one of the oldest drugs in use today (Wardrop and Keeling 2008), and its 
story begins in 1916 with medical student Jay McLean working in William Howell’s Physiology 
lab at Johns Hopkins. While working to isolate pro-coagulants from tissues, McLean observed 
anticoagulant activity in some samples (McLean 1916, McLean 1959). Liver was the best 
source for the anticoagulant, hence the name heparin (Howell and Holt 1918). Howell and 
coworkers initially believing heparin was a type of phospholipid (Barrowcliffe 2012)  However in 
1925 they uncovered evidence it was a carbohydrate, and published an aqueous 
extraction/organic precipitation method that is still the basis of heparin isolation (Howell 1925). 
Charles Best was another important figure In heparin development, whose group produced a 
crystalline heparin with 100 times improved purity, and began to produce it in large enough 
amounts to sell to other researchers (Scott and Charles 1933).  
The new, more pure heparin from the Best group opened the door for serious testing of 
heparin in animals and humans. Mechanical injury to veins was known to cause clotting, and 
heparin was seen as a way to prevent the often fatal complications with embolism which 
followed about 10% of surgeries (Murray and Best 1938). Experiments with dogs showed 




and physicians began administering heparin to patients following surgery (Murray and Best 
1938).  
Jorpes and coworkers first described heparin as a 1:1 composite of hexuronic acid and 
glucosamine, as well as identifying it as a sulfate ester and correctly predicting several sulfation 
sites (Jorpes and Bergstrom 1937). Jorpes also proposed the poly-lysine protamine as an agent 
for reversing the activity of heparin through neutralizing its negative charges; protamine is still 
the only approved heparin antidote (Jorpes, Edman et al. 1939).  
Later major developments in the development of heparin include the identification of L-
iduronic acid as a major constituent, which largely relied on the use of NMR (Lindahl 1966, 
Perlin, Mazurek et al. 1968, Perlin and Sanderson 1970). Not long after was the elucidation of 
the antithrombin binding pentasaccharide. Rosenberg’s group made the important discovery 
that heparin could be separated into two fractions with significantly different affinity to AT 
(Petitou, Casu et al. 2003). This implied the existence of a specific binding site. The site was 
eventually identified using chemically and enzymatically digested heparin, by isolating the high 
affinity AT-binding fragments and finding a common core (Lindahl, Backstrom et al. 1979, 
Lindahl, Backstrom et al. 1980).  
Newer heparin-based anticoagulants 
The advent of low molecular weight heparin (LMWH) marked the start of the 
development of pharmaceuticals based on heparin. LMWH is a partially depolymerized form of 
heparin about one-third the size of natural, unfractionated heparin (UFH). The MWavg for modern 
LMWH ranges from 3500-6000 Da, while the MWavg for UFH is about 16000 Da (Liu and 
Linhardt 2014). Edward Johnson and Barbara Mulloy first used gel-fractionation to separate 
heparin into molecular weight classes. In the first human study, the low-molecular weight 




compared to 1 h for full-size heparin (Johnson, Kirkwood et al. 1976). Rather than size 
fractionation, modern LMWH is prepared from UFH through enzymatic or base-catalyzed β-
elimination at uronic acid residues (Mulloy, Hogwood et al. 2016)  
  In addition to the slower elimination mentioned above, LMWH has desirable properties 
like higher bioavailability and more predictable dosing (Hirsh 1998). The smaller chain lengths of 
LMWH results in less off-target binding to basic plasma proteins than UFH. One of the most 
important aspects of LMWH is a reduced frequency of heparin induced thrombocytopenia (HIT), 
a life-threatening increase in clotting initiated by heparin binding to platelet factor 4 (PF4). 
Patients using LMWH only show about one-tenth of the HIT occurrences of those using  
(Arepally and Ortel 2010).   
 The total synthesis of the AT-binding pentasaccharide was published in 1984 (Sinay, 
Jacquinet et al. 1984). Eighteen years later, the synthetic drug fondaparinux entered the market 
in the US under the name Arixtra (Petitou and van Boeckel 2004). Fondaparinux is essentially 
identical to the heparin AT-binding sequence, with a methyl group on the reducing end to 
prevent ring opening, and a GlcNS6S group on the nonreducing end (see Figure 1.12, A). 
Fondaparinux binds AT with a KD of 50 nM (Petitou and van Boeckel 2004). For comparison, 
the KD of UFH is 19±9.0, and 58±15 nM for the LMWH enoxaparin (Lin, Sinha et al. 2001)  A 
major difference is the long half-life of fondaparinux; it has a 17 h half-life which allows it to be 
administered once daily unlike the multiple daily doses required for LMWH or UFH (Mulloy, 
Hogwood et al. 2016).  
 The drugs UFH, LMWH, and fondaparinux, are heavily used for the treatment and 
prevention of venous thrombosis (VE), a condition where a clot originates in a vein and forms a 
blockage in the lungs (Mackman 2008). VE is a serious public health concern diagnosed in as 




diagnosed with VE die within thirty days (Beckman, Hooper et al. 2010). Other indications of 
UFH and LMWH include treatment of atrial fibrillation (Lip, Windecker et al. 2014) coronary 
angioplasty (Howard, Antoniou et al. 2014) and cardiac bypass (Rozental and Shore-Lesserson 
2012).   
Other anticoagulants 
The vitamin K antagonists have been in use for several decades, with the most well-
known being warfarin. They inhibit the enzyme vitamin K epoxide reductase, disabling the 
recycling of the vitamin K coenzyme, which is required for post-translational modification of 
glutamate residues on factors VII, IX, X, and II  (Mackman 2008). This mechanism, which 
prevents the chelation of calcium ions (by the modified glutamate residues) required for 
assembly of clotting factor complexes, results in a long-time of onset. An advantage  of the 
vitamin K antagonists is they can be taken orally, and are often used for long-term anticoagulant 
therapy (Mackman 2008).  
Hirudin is a peptide derived from the leech Hirudo medicinalis that targets thrombin 
directly, with part of the peptide inserting into the active site of thrombin (Rydel, Ravichandran et 
al. 1990). Hirudin is the most powerful natural inhibitor of thrombin and has a KD in the 
femtomolar range (Stone and Hofsteenge 1986). Recombinant forms of hirudin have entered 
the market, for example lepirudin (Garcia, Baglin et al. 2012).  
Over the last twenty years a number of small molecule anticoagulants have emerged, 
which directly target either factor IIa or Xa. Argatroban is a small molecule that targets the active 
site of thrombin as a competitive inhibitor, but it must be given intravenously. (de Kort, Buijsman 
et al. 2005) Dabigatran was approved in 2010. It similarly targets thrombin, but is orally active 
and is one of the first in the class of novel oral anticoagulants (NOAC). Its indications include 




been developed. One of the problems with the NOACs is bleeding, an effect common to all 
anticoagulants, and the antidotes to NOAC drugs are being developed. In 2015 an antibody 
reversal agent was approved for dabigatran in the US (Pollack, Reilly et al. 2015). Although no 
reversal agents for the anti-Xa inhibitors have come on the market, andexanet alfa is a 
catalytically inactive factor Xa decoy currently in clinical testing (Siegal, Curnutte et al. 2015) 
Finally, the non-biologic, small molecule reversal agent  PER977, a symmetrical small molecule 
that is reported to reverse a spectrum of Xa and IIa targeted NOACs, as well as LMWH, is being 
developed (Ansell , Bakhru  et al. 2014). Because of the constant threat of hemorrhaging 
associated with anticoagulant use, the availability of cost-effective reversal agents for LMWH 
and/or NOACs would be an important development in the field.  
Problems with animal-sourced heparin 
 Although animal tissue-derived heparin has been the source of heparin since its 
beginning, this remains a point of controversy and concern. The annual usage of heparin is over 
100,000 kg, and this relies on the availability of pigs to insure a steady heparin supply. With 
1500-2000 pigs required for a single kg of heparin, the production of world demands of heparin 
requires hundreds of millions of pigs per year, and members of the US government have 
expressed concerns about shortages of the animal affecting the heparin supply (Tremblay 
2016). Fear of bovine spongiform encephalopathy that arose in the 1990s required all heparin to 
be from porcine sources (Tremblay 2016). Crude heparin is prepared by aqueous extraction of 
the intestinal mucosa, followed by purification with anion exchange chromatography, and 
subsequent precipitation with organic solvent (Szajek, Chess et al. 2016) The product of this 
extraction then undergoes careful purification steps to remove contaminants like heavy metals, 
viruses, bacterial endotoxins, and other GAGs. This leads to concerns about the thoroughness 




In 2008, a heparin contamination crisis occurred when heparin was intentionally 
adulterated with oversulfated chondroitin sulfate, which led to the loss of over 200 lives 
(Hedlund, Coyne et al. 2013). The multi-stage, de-localized nature of the heparin production 
process makes oversight difficult, and because the majority of heparin comes from China, 
access by US agencies can be complicated. For example, Beijing Shunxin Meihua Bio-technical 
banned the FDA from its facilities in 2014 which resulted in the FDA banning its heparin import 
to the US (Tremblay 2016).Since the discovery of the contamination, adulterated heparin has 
been linked to twelve factories (Hedlund, Coyne et al. 2013). As recently as 2016 the House 
Committee on Energy and Commerce expressed concerns about the lack of adequate 
protection against intentional contamination to the head of the FDA (Tremblay 2016). 
The HIT dilemma 
 The second major problem with animal-sourced heparin lies in the complication known 
as heparin induced thrombocytopenia (HIT). This is mostly associated with the use of UFH, and 
surgical patients administered UFH exhibit a HIT rate of 3% (Arepally and Ortel 2010). As 
mentioned previously, LMWH show a HIT rate about one-tenth of this. UFH can lead to the 
paradoxical clotting effects observed in HIT when the anionic UFH chains form complexes with 
the basic protein platelet factor 4 (PF4). These complexes are in turn recognized by antibodies 
that activate platelets and cause a thrombin increase that leads to potentially deadly clotting 
(Warkentin 2015). Early detection of developing HIT has proven difficult (Arepally and Ortel 
2010). Patients who show evidence of HIT must be taken off of UFH and moved to an alternate 
anticoagulant, usually the direct thrombin inhibitor argatroban in the US, although fondaparinux 






Why still use heparin? 
In spite of the problems with heparin production and HIT, both UFH and LMWH continue 
to be staple clinical anticoagulants. LMWH comprised a 27.8% fraction of the $23.5 billion US 
antithrombotic drug market (Chaudhari, Hamad et al. 2014). Furthermore, although the newer 
LMWH offer several advantages over UFH, there are clinical situations where UFH is the 
necessary choice. In procedures that require the use of extracorporeal blood flow, such as 
cardiac bypass, UFH remains the primary choice (Ferraris, Brown et al. 2011). Trauma to the 
blood under these conditions necessitates high doses of anticoagulant, but this must be 
balanced against the risk of hemorrhaging (Bevan 1999). Here UFH is preferred for several 
reasons. The level of its activity in blood can be rapidly assessed with the point of care test 
known as the active clotting time assay (ACT). Because LMWH only partially inhibits factor IIa, 
UFH is required for the ACT (Bates and Weitz 2005). In case of bleeding, only UFH can be fully 
reversed with protamine, which is also the only available heparin reversal agent (Cosmi 2015). 
UFH is also rapidly cleared from the blood (Alban 2008). Finally, because of differences in 
elimination routes, UFH is safe for kidney-impaired patients, while LMWH must be reduced, and 
fondaparinux is contraindicated (Harder 2012). 
Heparin chemical synthesis 
The synthesis of well-defined heparin structures has proven to be extremely challenging. 
Fondaparinux, arguably the most important synthetic achievement for any GAG, entails a 55 
step synthesis (Petitou and van Boeckel 2004). Employing a methyl glycoside to eliminate ring-
opening at the reducing end, Petitou et al reported a synthesis involving the glycosidic linkage of 
a trisaccharide to a disaccharide containing the crucial iduronic acid. Another key feature was 
the use of different protecting groups for hydroxyls destined for sulfation (benzyl ester) and 




from 2013 that describes a shorter synthesis of the pentasaccharide (36 steps), the overall yield 
starting from glucose monomers is 0.017% (Lin, Lian et al. 2013).  
Considering the challenges posed by the synthesis of fondaparinux, increasing the size 
of the oligosaccharides to the size of LMWH or larger would clearly present difficulties for a 
viable, scalable synthesis. Recently, homogenous heparin molecules as large as a 20-mer have 
been chemically synthesized, but these structures are composed of the repeating trisulfated 
heparin disaccharide (Hansen, Miller et al. 2015). For thorough structure-activity studies, it is 
necessary to synthesize oligosaccharides with a variety of disaccharides. However, this poses 
challenges with optimizing protective groups for the many possible HS disaccharides. 
Furthermore, most synthetic heparins contain solely iduronic acid as the stereochemistry of the 
glucosamine to glucuronic acid linkage is more difficult to control (Dulaney and Huang 2012).  
Although chemical synthesis of HS remains an imposing obstacle, great strides have 
been made in the synthesis of HS oligosaccharides with variable disaccharides. There has been 
a trend emphasizing a modular approach to HS synthesis, joining protected precursor fragments 
(Arungundram, Al-Mafraji et al. 2009). This has been recently applied for the synthesis of 
idraparinux, an O-methylated analog of fondraparinux (Dey, Lo et al. 2019). In 2019 a 
collaborative group published a method to prepare four key HS disaccharides from readily 
available polysaccharides. Thus, ready access to cost-effective starting materials may enable 
more viable syntheses (Pawar, Wang et al. 2019). Automated methods have also been 
explored, including the synthesis of chondroitin sulfate oligosaccharides ((Eller, Collot et al. 
2013), and more recently for the automated synthesis of an HS hexasaccharide from 
disaccharide precursors (Budhadev, Saxby et al. 2019).  
To offset the difficulties associated with the synthesis of full natural products, some 




simplified scaffold. Soon after Petitou and co-workers prepared the factor Xa inhibitor 
fondaparinux, they began work on structures targeted to factor IIa. Although there was no 
ternary complex available at the time, modeling indicated IIa and AT bound to separate regions 
of the heparin chain (Grootenhuis, Westerduin et al. 1995). The group constructed a series of 
thrombin inhibitor heparin mimetics consisting of a sulfated maltotriose or maltopentose 
(thrombin-binding domain mimic) with a polyethylene glycol linker to an AT-binding 
pentasaccharide. One highly sulfated maltopentose with a 59-atom bridge to the AT-binding 
domain exhibited more potent IIa inhibition than heparin (Grootenhuis, Westerduin et al. 1995). 
A similar linking strategy was applied to HS-mimetics targeting gamma-interferon. The reducing 
ends of HS tetra- to octasaccharides were connected through a polyethylene glycol linker 
through a UV-catalyzed coupling of a thiol and allyl group (Lubineau, Lortat-Jacob et al. 2004).  
HS and heparin chemoenzymatic synthesis 
Employing naturally occurring enzymes alongside traditional chemical methods to 
facilitate the synthesis of HS, a technique known as chemoenzymatic synthesis, has also 
proven to be a fruitful synthetic approach. The high regio- and stereo-selectivity of enzymes 
allows for precise control of sulfation, epimerization, and formation of gycosidic bonds, 
eliminating the need for protection and deprotection steps (Figure 1.14). Jian Liu’s group at 
UNC has pioneered the application of chemoenzymatic methods to HS synthesis (Xu, Masuko 
et al. 2011). The laboratory has expressed all of the HS sulfotransferases along with C5-
epimerase (Zhou, O'Leary et al. 2012). To prepare well-defined HS oligosaccharides with the 
chemoenzymatic approach, bacterial glycosyltransferases act on UDP-GlcA or UDP-GLcNAc 
(which are themselves chemoenzymatically synthesized from monosaccharide precursors) to 
sequentially elongate the oligosaccharide backbone. which can be strategically modified by C5-
epimerase and sulfotransferases in accordance with their substrate specificity. The 






Figure 1.14. Scheme for chemoenzymatic synthesis of an AT-binding hexasaccharide. The 
glycosyltransferases KfiA or PMHS2 act on UDP-sugars to elongate the chain, which is sulfated by 
sulfotransferases or epimerized by C5-epimerase.  
The synthesis typically begins with a glucuronic acid aglycone displaying a para-
nitrophenol for UV detection and purification with reverse phase chromatography. A key step is 
the introduction of N-sulfation, using a GlcNAc where the acetyl has been substituted with a 
bioisosteric trifluoroacetyl group (GlcNTFA). The glycosyltransferase will incorporate GlcNTFA 
into the oligosaccharide chain, where it can be de-trifluoroacetylated using lithium hydroxide, 
and subsequently sulfated with the N-sulfotransferase domain of NDST (Liu, Xu et al. 2010). 
This N-sulfation is required for the action of the Hsepi and 2OST to construct the major 
disaccharide found in heparin. However, to synthesize domains with this repeated IdoA2S-
GlcNS6S requires controlling the reversibility of the Hsepi. This can be accomplished with a 
glucuronic acid that is directly flanked by GlcNS, with a GlcNTFA as the third monomer toward 




epimerization reaction toward the formation of IdoA, which can then be acted on by 2OST 
(Sheng, Xu et al. 2012). 
This chemoenzymatic synthesis has been carried out from microgram to gram scale. A 
gram scale chemoenzymatic synthesis of heparin-like dodecasaccharides showed anticoagulant 
activity comparable to UFH heparin, and was reversible with protamine (Xu, Chandarajoti et al. 
2017). The chemoenzymatic approach also allows access to a great variety of HS structures. 
Recently a library of hepta- to dodeca-saccharides was used in a micro-array format to uncover 
the affinity of tau protein for 3-O-sulfated HS oligosaccharides (Zhao, Zhu et al. 2020). The 
following chapters will explain my work to expand on enzymatic and chemical methods to 
synthesize HS/heparin mimetics, and to characterize the substrate specificity of a novel enzyme 














STATEMENT OF THE PROBLEM 
Heparin is an anticoagulant drug derived from animal tissues, with a multi-stage supply 
chain that has proven prone to contamination (Liu, Zhang et al. 2009).  Its heterogeneous 
structure complicates efforts to verify purity and contributes to side effects like heparin induced 
thrombocytopenia. Nonetheless, heparin has implanted itself deep into clinical practices over its 
nearly ninety years of use. Current heparin pharmaceuticals include full-size, unfractionated 
heparin (UFH), low molecular weight heparin (LMWH), and the synthetic pentasaccharide 
fondaparux. Among available anticoagulants, only unfractionated heparin (UFH) is amenable to 
the standard point of care assays used to measure anticoagulant activity (Linkins, Julian et al. 
2002). It has a short half-life that offsets bleeding risks, and only UFH can be readily 
neutralized. UFH is also safe to use in patients with impaired kidney function (Grand'Maison, 
Charest et al. 2005).  All of these features are a function of the comparatively large size of UFH 
polysaccharide chains.  
Ideally, synthetic heparin could preserve the desired features of UFH while reducing side 
effects, but its approximately 25 disaccharide size renders it essentially beyond reach for 
traditional chemical synthesis. Here, we combine chemoenzymatic and modular synthesis 
techniques, using the copper catalyzed azide-alkyne cycloaddition (CuAAC) to link 
chemoenzymatically synthesized oligosaccharides. We synthesized a series of homogeneous 
heparin mimetics ranging in size from a 4-mer up to a 24-mer. Based on the structure of a factor 
IIa – antithrombin complex bound to a heparin analog, we hypothesized the linked compounds 
would have anti-coagulant activity comparable to that of natural heparin. A workflow was 
developed to functionalize oligosaccharides with the linker, alkyne, and azido groups required 
for linking with the CuAAC reaction. We then synthesized a series of heparin mimetics and 
measured their binding to factor Xa and factor IIa, as well as their activity in the active clotting 




heparan sulfate oligosaccharide produced in our lab and may be extended to explore other 
heparan sulfate binding oligosaccharides.  
Analysis of biologically sourced HS and heparin is another problem. Typically, these 
polysaccharides are digested to disaccharides by either an enzymatic or chemical treatment, 
giving a “disaccharide fingerprint” of the relative amounts of each of the component 
disaccharides. However this does not uncover information on the linear sequence of 
modifications in the polysaccharide chains. In spite of their biological prevalence, the sequence 
of modifications in HS is poorly understood. Although the heparinase enzymes are standard 
tools for the disaccharide analysis of HS, the addition of more HS-active enzymes could bring 
the goal of HS sequencing closer to reach. We investigated a lyase-type enzyme that cleaves 
HS, and showed it has a specificity that is highly sensitive to single modifications of the 
polysaccharide backbone. More information on the specificity of K5 lyase may allow it to be 















CHAPTER 2: DEVELOPMENT OF “CLICKED” MODULAR HS MIMETICS 
Introduction 
The copper catalyzed azide-alkyne cycloaddition (CuAAC) was independently reported 
by the Meldal and Sharpless groups in 2002 (Rostovtsev, Green et al. 2002, Tornoe, 
Christensen et al. 2002). It is part of a set of reactions commonly referred to as “click chemistry”. 
Other examples include thiol-ene addition reactions, the Diels-Alder cycloaddition, nucleophilic 
ring openings of epoxides, and the Staudinger ligation. “Click” reactions tend to be highly 
exergonic, tolerant to a wide range of conditions, yield a well-defined product, and give 
byproducts that can be easily removed (Kolb, Finn et al. 2001). A click reaction is usually 
intended to link diverse chemical entities, often in a combinatorial fashion. Applications include 
library synthesis, polymer synthesis, and bioconjugation (Kolb and Sharpless 2003, Elchinger, 
Faugeras et al. 2011, Thirumurugan, Matosiuk et al. 2013). A special advantage of the CuAAC 
is its bioorthogonality. Because the azide and alkyne groups are essentially unreactive towards 
nearly all of the functional groups in biological molecules, they remain selective to one another 
even among the large chemical variety of a biological environment.  
The CuAAC has been applied to many types of polysaccharides (Elchinger, Faugeras et 
al. 2011). Work involving heparin or HS appears to have mostly used naturally sourced, 
heterogeneous heparin. Applications include the formation of hydrogels through heparin 
polysaccharide crosslinking, or the functionalization of bio- and nanomaterials with heparin 
(Reyes-Ortega, Parra-Ruiz et al. 2013, Tsurkan, Chwalek et al. 2013, Liang and Kiick 2014, 
Dimitrievska, Cai et al. 2015). In 2012 Liu et al. applied the CuAAC to generate a library of 




disulfated mannose (Liu, Moon et al. 2012). In 2014 several chemically protected HS mono-, di-, 
and tetra-saccharides displaying a reducing-end allyl group were fused with an amino-linker 
moiety using thiol-ene chemistry. Although these were protected HS species, they are the 
largest non-heterogenous HS used in a “click” type reaction (Povie, Tran et al. 2014). 
 Many researchers have approached the chemical synthesis of HS from a modular 
perspective (Seeberger 2015). The formation of a glycosidic linkage between two saccharides is 
one of the fundamental steps in the chemical synthesis of glycans. The anomeric carbon of one 
saccharide (the donor) carries a leaving group and is attacked by a nucleophile on the acceptor, 
usually an unprotected hydroxyl group (Kiessling and Splain 2010). Precisely controlling the 
regio- and stero- chemistry of this bond formation can be difficult and is influenced by many 
factors, such as the type of carbohydrate, protecting groups, and solvent  (Kiessling and Splain 
2010, Seeberger 2015).  Therefore, ways to generalize the conditions for the formation of 
glycosyl bonds are sought after (Orgueira, Bartolozzi et al. 2003, Prabhu, Venot et al. 2003, 
Codee, Stubba et al. 2005).  In early work on the modular synthesis of HS, Arungundram et al. 
built a library of twelve tetrasaccharides. They point out how a modular, parallelizable approach 
greatly expands the efficiency with which libraries of HS structures can be synthesized 
(Arungundram, Al-Mafraji et al. 2009).   
Block co-polymer HS mimetics 
Here we extend upon this modular approach, employing the CuAAC reaction to link 
azide and alkyne functionalized HS oligosaccharides. A crucial aspect of this method is the size 
of the modular building blocks. Rather than joining monosaccharides or disaccharide building 
blocks, we link larger HS fragment ranging from penta- to dodeca-saccharides.  Each block, or 
domain can be chemoenzymatically synthesized in relatively few steps and can yield a variety of 




The scaffolding function of HS is a well-documented phenomenon (Lindahl, Kusche-
Gullberg et al. 1998, Xu and Esko 2014). HS can act as a scaffold that facilitates binding 
between proteins, as seen in the formation of the ternary complex of FGF and its receptor 
(Figure 2.1). On the other hand, HS acts as a scaffold in a broader context, binding growth 
factors and cytokines on the cell surface and extracellular matrix to establish biochemical 
gradients (Bernfield, Gotte et al. 1999). In both cases, HS chains of considerable size (~ 
decasaccharide size or more) are required, making it laborious to obtain structurally-defined HS 
required to study these phenomena. The HS components that bind proteins have been shown 
to have discrete sizes, according to mutational analysis of HS binding sites in proteins, x-ray 
crystal structure HS-protein complexes, and molecular modeling that indicate proteins bind HS 
fragments with a specific size (Kreuger, Spillmann et al. 2006, Liu, Sheng et al. 2014). Linking 
two or more oligosaccharides with a relatively small, flexible linker should preserve both the 
specificity and scaffolding function of HS polysaccharides. The synthesis of these mimetics 
could be done in parallel, allowing for faster creation of larger HS libraries.  Figure 2.1 illustrates 
the sizes of HS oligosaccharides bound to different proteins. To carry out the conjugation of the 
oligosaccharides with the CuAAC, we functionalized the reducing end of one oligosaccharide 







Figure 2.1. The CuAAC to link HS protein-binding domains.  A) Examples of globular proteins bound 
to HS illustrate the dimensions of a typical protein binding segment of HS. Distances shown illustrate the 
linear measurement from the reducing end 1-C to the opposite end 4-C. Left (2-OST) depicts a p-
nitrophenol labeled heptasaccharide substrate (PDB 4NDZ). Middle is a ternary complex of FGFR2 and 
FGF1 bound to a heparin decasaccharide. The 17.6 Å pentasaccharide segment contacts both FGF1 
chains. The other 18.9 Å half of the decasaccharide binds at the interface of an FGF1 and FGFR2 chain 
(PDB 1E0O). The AT III is depicted bound to a synthetic allosteric activator (PDB 1AZX).  B) For fusion 
through the triazole linker, one oligosaccharide displays a reducing-end alkyne linker. The nonreducing 
end of the other component contains an azido group on the α- position of the GlcNAc acetyl (i.e., 
GlcNAz). 
 
Derivatization of primer monosaccharide 
 In the chemoenzymatic syntheses done in the Liu lab, the reducing end residue of each 
compound is a GlcA with a β-glycosidic linkage to a para-nitrophenol (-pNp) group. Each 
synthesis begins with the enzymatic elongation of this GlcA-pNp “primer”. The -pNp UV 
absorbance signal is used to detect the oligosaccharides during chromatographic purifications 
and analyses. Because it would be furthest from the target protein binding site, the phenyl group 
was investigated as the point of attachment for the alkyne/linker. A general approach was 




modified with nitrosylated tyrosine (Nikov, Bhat et al. 2003, Kim, Lee et al. 2011). In these 
works, the authors reduced the nitro group on the nitrosylated tyrosine group to an amine, which 
was then labeled through coupling with an N-hydroxy-succinimide ester.  
To carry out the reduction of the nitro group, a method for the reduction of unprotected 
GlcNAc-β-pNp was adapted to GlcA-pNp (Roy and Tropper 1991) (Ram and Ehrenkaufer 
1988). The monosaccharide was treated with 10% Pd/C in methanol, with ammonium formate 
as a hydrogen source.  Analysis of the product with negative mode electrospray ionization mass 
spectrometry showed the expected 30.0 Da  reduction in the molecular weight corresponding to 
reduction of the nitro group to an amine.  However, HPLC detection of the reduced product was 
difficult, perhaps because protonation of the aniline group in the conditions of the HPLC 
destroyed UV absorbance. Comparison of the UV absorbance spectra of the Glc-pnp starting 
material and the GlcA-p-aminophenol (GlcA-pap) product showed a lower molar absorbance, 
and no significant signal at wavelengths longer than 315 nm.  
 
Biotinylation of an HS pentasaccharide: 
Biotinylation is a valuable and widespread technique in chemical biology and 
glycobiology. For example, a Fuc-Gal disaccharide conjugated to biotin has been used to probe 
for fucose binding sites on neurons (Kalovidouris, Gama et al. 2005), and a biotinylated analog 
of the AT-binding pentasaccharide that could be neutralized with avidin has been investigated 
(Harenberg 2009).  We reasoned that reduction of the reducing-end para-nitrophenol group to 
para-aminophenol  should allow for conjugation to biotin through treatment with a N-
hydroxysuccinimide-biotin (NHS-biotin) ester. Although NHS-esters are most often used for 
conjugation to primary amines, work by Kim et al indicated aromatic amines can also be 
selectively labeled (Kim, Lee et al. 2011). 
The monosaccharide GlcA-pap was first tested as a substrate for biotinylation. This was 




chromatography and confirmed with mass spectrometry. A parallel reaction with GlcA-pNp 
showed no reaction by mass spectrometry analysis, indicating conjugation likely occurred 
through the aminophenol moiety. We hyposethized this same reduction/biotin-conjugation 
procedure could be extended to larger HS ologosaccharides. An N-sulfated pentasaccharide 
was first reduced then subsequently treated NHS-biotin under conditions analgous to that for 
the GlcA-pNp monosaccharide. The biotinylated product was verified with mass spectrometry, 
and analysis on an anion-exchange column showed a peak eluting 1.1 minutes later than the N-
sulfated pentasaccharide starting material, but lacking the UV signal at 310 nm characteristic of 
the p-nitrophenol group (Figure 2.2). 
 
Figure 2.2. Biotinylation of GlcA and an N-sulfated pentasaccharide.  A. GlcA-pnp was reduced to 
the aminophenyl analogue and biotinylated in two steps. B. Non-reduced GlcA-pnp did not couple with 
NHS-biotin. C. The N-sulfated pentasaccharide-pnp was successfully reduced and biotinylated. D. HPLC 
trace of the biotinylated pentasaccharide on a polyamine column. The 310 nm signal used to detect –pnp 
labeled saccharides shows no response, so there is no remaining starting material. The retention time for 





Linker optimization:  
The linked HS mimetic should exhibit enough flexibility to adapt to  binding of its protein 
targets, while retaining enough rigidity to function effectively as a scaffolding template. Highly 
sulfated heparin is thought to be fairly rigid, with with “rod-like” conformation in solution (Mulloy 
and Forster 2000).  However, the flexibility of iduronic acid groups (caused by the skew-
boat/chair equilibrium) and recent work indicating greater flexibility in non-sulfated HS, show 
that the flexibility of HS is nuanced (Mulloy and Forster 2000, Khan, Fung et al. 2013).  In the 
work of Petitou’s group, a synthetic AT-binding pentasaccharide was linked to a IIa binding 
trisaccharide with a linker of 53 carbons (Grootenhuis, Westerduin et al. 1995). Although this 
structure did exhibit anti-factor IIa activity, when the same oligosaccharides were linked with a 
contigous polyglucose sequence the anti-IIa activity increased by a factor of 30 ((Petitou and 
van Boeckel 2004)). The increased flexibility of the carbon chain clearly introduced an entropic 
penalty (Bonnaffe 2011).  
The linkers we required would need to have the 1-carbon as a carboxylic acid (to form 
an amide bond to the aniline group) and a terminal alkyne appended to the opposite end.  We 
considered linkers containing 5, 7, and 10 carbons (4-pentynoic acid, 6-heptynoic acid, and 9-
decynoic acid, respectively). To visually compare these linkers, molecular models were 
constructed and the local geometry was minimized using the software Schrodinger 14.2 (Figure 
2.3). The seven carbon linker appeared to allow free rotation of the linked saccharides without 
steric clashing, without allowing for too much movement between the HS components. Of 
course, the full range of conformational dynamics is difficult to visualize from a static model. An 
10 ns molecular dynamics simulation was done in water (with 150 mM NaCl) with compound B 





Figure 2.3. Molecular modeling of linkers. Structures A through C represent triazole linked GlcA-
GlcNAz models with linkages with 5, 7, and 10 carbon chain with alkanoic acid linkers, respectively.  
Panel D, molecular dynamics was used to visualize the behavior of linkage in B. Compound B was 
simulated in water at 400 K and the temperature was linearly interpolated 300 K. High temperatures  lift 
the model out of local energy wells and  then “cooled” to room temperature. The final frame of the 
simulation is shown, measuring 15.3 Angstroms from the GlcA 1-carbon to the GlcNAz 4-carbon.  
 
Conjugation with alkyne linker: 
 
To introduce the terminal alkyne required for the CuAAC fusion,  the hept-6-ynoic acid 
linker was coupled to the nitro-reduced form of GlcA-pNp. The alkyne/linker labeled 
monosaccharide can then be extended by chemoenzymatic synthesis to provide the 
oligosaccharide for the “click” reaction. To bypass the synthesis of the water-sensitive NHS-
hept-6-ynoic acid ester (2,5-dioxopyrrolidin-1-yl hept-6-ynoate) the heptyne linker was directly 
linked to GlcA-pAp by forming an amide bond with 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC). Although EDC coupling introduces the risk of 
dimerization of the GlcA-pAp, this is likely to be sterically disfavored, and was further avoided by 
using an excess of hept-6-ynoic acid. The crude product was purified using reverse phase 
chromatography, leaving residual excess hept-6-ynoic acid. The product was isolated from 
heptynoic acid with size exclusion chromatography with a yield of 69% followed by NMR 





Figure 2.4. GlcA conjugated to terminal alkyne linker.  After EDC coupling of hept-6-ynoic acid to 
GlcA p-aminophenol, the product was purified on biogel-P2 (size exclusion chromatography). Top panel 
shows proton 1D NMR, bottom shows electrospray ionization mass spectrum. The peak at 392.27 m/z 






Table 2.1. NMR assignments for GlcA conjugated to heptyne linker  
 
Synthesis of azido-labeled HS oligosaccharides 
 To maintain the directionality of the linked oligosaccharides required the nonreducing 
end of the oligosaccharides was labeled with the azido group. To do this, we looked to 
pioneering work done by the Bertozzi laboratory combining click chemistry with glycobiology 
(Agard and Bertozzi 2009). In particular, the group incubated azido-labeled monosaccharide, N-
azidoacetylglucosamine (GlcNAz) with cells, which was subsequently metabollically 
incorporated into cell-surface glycans (Saxon, Luchansky et al. 2002). As in our own 
chemoenzymatic syntheses, for GlcNAz to be incorporated into glycans it must first be 
converted into uridine 5’-diphosphate-GlcNAz (UDP-GlcNAz), and then added to the nascent 
oligosaccharide chain by glycosyltranferases. This sugested that the enzymes used in our in 
vitro chemoenzymatic syntheses may tolerate GlcNAz. Therefore, we began with an enzymatic 
approach to incorporating GlcNAz into the HS oligosaccharides. First, GlcNAz was synthesized 
from glucosamine hydrochloride by coupling to azidoacetic acid with the carbodiimide EDT, 
based on the synthesis of azidosugars by the Bertozzi group (Luchansky, Hang et al. 2003). 
After synthesis of the GlcNAz starting material, three enzymatic steps are required to 




To add GlcNAz onto the reducing end of a sugar, first N-acetylhexosamine 1-kinase 
(NahK) phosphorylates the anomeric oxygen on GlcNAz, followed by N-acetylglucosamine-1-
phosphate uridyltransferase (GlmU) completing the synthesis of UDP-GlcNAz. Then, N-acetyl 
glucosaminyl transferase from Escherichia coli K5 (KfiA) can catalyze transfer of the GlcNAz to 
the oligosaccharide from the UDP-GlcNAz. In spite of suggestions that the azidoacetyl group 
would be well-tolerated by the synthetic enzymes, at the beginning of the project only NahK had 
definitively been shown to accept GlcNAz (in the 1-phosphorylated form) as a substrate. To 
establish the feasibility of an enzymatic method for the introduction of the GlcNAz, we 
succesfully carried out the synthesis of UDP-GlcNAz, and tested its addition to two chemically 
diverse substrates. First was a relatively small tetrasaccharide comprised of –GlcNAc-GlcA- 
residues, and the second was a heptasaccharide containing N-sulfation, 2-O-sulfation, and 
epimerization (Figure 2.5). For each of the oligosaccharide substrates, the GlcNAz terminated 






Figure 2.5. Addition of GlcNAz to HS oligosaccharides with glycosyltransferase KfiA.  
 
CuAAC linking of HS oligosaccharides 
 The cycloaddition of alkynes with azides was first noted by Michael in 1893, who 
reported a product mixture consisting of triazole isomers (Berg and Straub 2013). In the 1960’s 
Huisgen elucidated the mechanism of the reaction as a 1,3 dipolar cycloaddition. The 
uncatalyzed reaction is highly favored thermodynamically, with a release of greater than 20 
kJ/mol (Aragao-Leoneti, Campo et al. 2010). However, it is kinetically disfavored and requires 
high temperatures and multiple days of reaction time. The product of the uncatalyzed azide-
alkyne cycloaddition is a 1,2,3-triazole, which appears in an approximate 1:1 mixture of 1,5- and 
1,4- disubstituted isomers.  The utility of this reaction was greatly expanded after the discovery 
of the catalytic effect of Cu(I). The Cu(I) catalyst increases the reaction rate by a factor of about 




within a few hours. The large negative ΔG associated with the formation of the aromatic triazole 
ring drives the reaction to high yields. Importantly, the Cu(I) catalyzed mechanism insures that 
only the 1,4 regioisomer results. The cycling of the Cu oxidation state and the Cu ligand 
structure make the exact nature of the mechanism a topic of ongoing research (Berg and Straub 
2013). It is clear, though, that the alkyne must be terminal, which allows for removal of the acidic 
terminal alkyne proton and an intermediate that results in the 1,4 disubstituted isomer. Also, 
Cu(I) is required. Different approaches for the generation of Cu(I) include reduction of Cu(II), 
such as the reduction of Cu(II) to Cu(I) by ascorbate, or the direct addition of Cu(I) in the form of 
copper(I) iodide or other cuprous halides. The reaction can proceed in either organic, mixed, or 
aqueous solvents.  
 A potential obstacle with the use of the CuAAC on HS compounds is the susceptibility of 
HS and heparin to Cu(II) induced free radical degradation (Liu and Perlin 1994). Liu et al. 
reported an approximate 50% decrease in heparin anti-factor Xa activity after treatment of the 
heparin with Cu(II), hydrogen peroxide, and ascorbate. Similar effects have been observed with 
other glycosaminoglycans. It was later shown that Cu(II) was preferentially coordinated at the 
Ido2S-GlcNS6S disaccharide in a tetragonal ligand conformation (Rudd, Skidmore et al. 2008). 
This chelation of Cu(II) appears to make heparin especially susceptible to oxidative damage.  
 Beyond the potentially degradative effects of Cu(II) on heparin is the problem of the 
general cytotoxicity of copper on the cellular environment (Kennedy, McKay et al. 2011). 
Because we chose the CuAAC method for linking HS in part because it was bioorthogonal and 
left the option of performing “click” reactions in the presence of other biomolecules, this was a 
problem we needed to address. Bertozzi and her group was able to carry out work with 
metabolic labeling using azide-alkyne click chemistry by substituting the terminal alkyne used in 
the CuAAC with a cyclooctyne that did not require Cu(I) catalyst (Baskin, Prescher et al. 2007). 
The conformational strain in the cyclooctyne ring effectively lowered the kinetic energy barrier to 




Prescher et al. 2007). Because of the potentially damaging effect of Cu(II) on our synthetic HS 
fragments, we considered the use of the cyclooctyne rather than the terminal alkyne. While it 
worked well for labeling experiments, for our purpose it posed several problems. One, the 
cycloctyne is considerably bulky, especially after fusing with the azide. For linking of two 
oligosaccharides, we believed it would be best to keep the steric bulk of the linkage to a 
minimum so as not to interfere with binding of the linked HS oligosaccharides to a potential 
protein target. A bulky linker could also restrict the movement of the linked oligosaccharides. 
Second, unlike the copper-catalyzed azide-alkyne cycloaddition, the strain-promoted 
cycloaddition with cyclooctynes yields two regioisomers (Sletten and Bertozzi 2011). Employing 
the CuAAC would insure a single well-defined product in high yield.  
 Around 2009, reports began to emerge of CuAAC catalysts that could counter the 
cytotoxic, oxidative damage of the reaction. Wu and collaborators were able to use the copper 
catalyzed Huisgen reaction for imaging of fucose in live zebrafish  (del Amo, Wang et al. 2010). 
These results are based on improvements of ligands that bind copper in the Cu(I) state, 
protecting from oxidative stress induced by cycling of Cu oxidation states (Hong, Presolski et al. 
2009). The first efforts to develop methods for CuAAC bioconjugation used a sulfonated 
bathophenanthroline, which was highly sensitive to oxygen and required special reaction 
conditions. Another class of ligands based on the tris(triazolylmethyl)amine structure has proven 
to work well for this purpose, while the enhancing overall rate of the reaction. We used the water 
soluble derivative tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) as a catalyst, which has 
been used in many bioconjugation prodecures, and shown to protect cells from cytotoxic effects 
of copper in vivo (Besanceney-Webler, Jiang et al. 2011, Presolski, Hong et al. 2011) 
 To test the robustness of our CuAAC protocol and identiify any type of HS modification 
that might interfere with the reaction, we synthesized a series of octasaccharides bearing a 
GlcNAz residue on the non-reducing end, and displaying various modifications typical of 




of oligosaccharides with an N-sulfated pentasaccharide. The presence of the linked 13-mer 




Figure 2.6. Testing for the effect of sulfation on the click reaction. A series of GlcNAz-labeled 
octasaccharides with sequentially increasing sulfation was reacted with an alkyne-tagged, N-sulfated 
pentasaccharide. The bottom panel shows the mass spectrum of the pentasaccharide linked to 
octasaccharide [D]. The octasaccharide D displayed all four types of HS sulfation, and contained the 






Synthesis and characterization of a CuAAC-linked tetrasaccharide (4-mer) 
The workflow for functionalizing and linking the HS oligosaccharides involves a series of 
chemical and enzymatic reactions. In order to thoroughly characterize the products of this 
process, we synthesized a simplified model system consisting of two linked disaccharides. The 
overall synthetic scheme is outlined in Figure 2.7.  
 
 
Figure 2.7. Scheme for synthesis of linked tetrasaccharide (4-mer) from GlcA-pNp and GlcNAz.  
Left column: The heptyne derivatized GlcA is a result of reducing the GlcA-pNp to yield an aromatic 
amine which is coupled to heptynoic acid with EDC. Using KfiA glycosyltransferase and UDP-GlcNAc 
gives the alkyne functionalized disaccharide. Right column: The UDP-GlcNAz is built from the succesive 
action of NahK and GlmU. KfiA is again used to yield the azido functionalized disaccharide. The CuAAC 
takes place under aqueous conditions and is used to link the disaccharides in the presence of the water 





The final tetrasaccharide product gave a yield of 61% for the CuAAC reaction step, and 
was characterized with ESI-MS, anion exchange HPLC, and a series of NMR experiments. As 
shown in Figure 2.8,  HPLC analysis indicated greater than 95% purity. High purity was also 
confirmed with NMR. The sum of integrals in the 1H NMR spectrum was set to 46, which is the 
number of non-exchangeable protons in the 4-mer. All anomeric protons integrate as nearly 1.0. 
The triazole ring proton resonates as a single peak. The four doublets in the aromatic region 
correspond with the linker protons L2 and L3, and the reducing end p-nitrophenol (not labeled). 
 
Figure 2.8. ESI-MS, HPLC, and 1H-NMR analysis of CuAAC linked tetrasaccharide. Panel A shows 
negative-mode ESI-MS signals, both of which are within 1 Da of theoretical. B. The compound eluted as a 
single peak on an ion exchange column. Panel C shows 1H-NMR spectrum with peals corresponding to 





Figure 2.9. 4-mer NMR 1H-13C heteronuclear single quantum correlation (HSQC) NMR experiment and 















Figure 2.10. 2D 1H NMR spectra. A. Nuclear Overhauser effect spectroscopy (NOESY) showing in-
space proximity of the triazole ring proton to the linker C-9 protons, illustrated with red line on the 
structure. B. Total correlated spectroscopy (TOCSY) shows coupling of the triazole ring proton to the 
GlcNAc α-carbon, shown in blue on the structure. C. Correlation spectroscopy (COSY).  
   











Figure 2.11. 4-mer NMR continued. A. 1H-13C heteronuclear multiple bond coupling (HMBC) illustrates a 
coupling chain from the triazole ring proteon to the linker amide C-5. B. 1-D 13C NMR spectrum.   
 
Conclusions 
Decades of synthetic work on heparin and HS-like oligosaccharides has proven their 
synthesis to be enormously challenging, with increases in difficulty as the size of the 
olgosaccharides increase. The modular, click-chemistry-based technique shown here can 
augment our established chemoenzymatic synthesis allowing for the rapid construction of 
oligosaccharide mimetics of considerable size. Furthermore, this method can be employed 
combinatorially, to quickly synthesize collections of HS mimetics composed of different 




residue to a previously linked structure, it could be possilbe to use succesive rounds of CuAAC 
reaction to build an HS-mimetic with more than one linkage.  
Incorporating the azido and alkyne groups into the oligosaccharides requires minimal 
alterations to the chemoenzymatic workflow. Because the GlcNAz residue is added to the non-
reducing end of an oligosaccharide by a glycosyltransferase, it is straightforward to add the 
azido group required for the CuAAC. To incorporate the alkyne-linker, we modified the GlcA-
pNp “primer” monosaccharide to display the alkyne-linker before further extending the 
oligosaccharide. However, our work on the biotinylation of the N-sulfated pentasaccharide 
shows it may be possible to modify oligosaccharides displaying a reducing-end para-nitrophenol 
to display the alkyne linker.  
Here we have developed a synthetic  process for the derivitization of HS 
oligosaccharides for the CuAAC reaction. The enzymes required for synthesis of the UDP-
GlcNAz were both tolerant to the the azido functional group, and the KfiA glycosyltransferase 
was able to add GlcNAz to oligosaccharides with various sizes and sulfation. Potential problems 
with the use of copper appear to have been mitigated with the use of the Cu(I) binding ligand 
THPTA. Linked products of the CuAAC reaction were detected for all types of sulfated 
oligosaccharides. Analysis of a linked 4-mer HS mimetic indicates this method yields a 
homogeneous, well-defined product of high-purity.   
Finally, this method does not have to be confined to heparin binding oligosaccharides. 
The long-standing success of heparin as a drug implies there may be other therapeutic HS-
based pharmaceuticals to be discovered. The protein scaffolding function seen with heparin is 
common among HS binding proteins (Xu and Esko 2014). For example, recent work has shown 
HIV-1 matrix protein p17 dimerizes on HS 15-mer chains (Bugatti, Paiardi et al. 2019). This 
method could provide access to a variety of HS structures with the sizes required for multi-
protein interactions.. Large contiguous HS oligosaccharides may not be needed to uncover.new 




mimetics in a microarray to identify HS-protein interactions. Using the linked HS-mimetics, 
promising leads could be identified, which could then be chemoenzymatically synthesized into 






























CHAPTER 3: MODULAR HEPARIN MIMETICS WITH ANTI-IIA ACTIVITY 
Introduction 
Heparin has been a mainstay anticoagulant drug since the 1930’s. Its complex structure 
and derivation from animal tissue have led to multiple issues (Liu, Zhang et al. 2009). The 
heterogeneous structure of heparin makes it difficult to verify its purity (Szajek, Chess et al. 
2016) and the FDA has continued to express concerns about heparin safety (Tremblay 2016). 
Furthermore, only about one-third of heparin chains contain the active pharmaceutical element 
of heparin, and superfluous sulfated chains contribute to off target effects. To further complicate 
things, viral infections in pigs threaten to disrupt the global heparin supply (Vilanova, Tovar et al. 
2019).These issues have led to an increased urgency for heparin alternatives. 
 
Heparin in the United States is currently sourced from porcine intestinal mucosa. 
Samples are first treated to chemically or enzymatically lyse the proteins, followed by 
enrichment of the released glycosaminoglycans on a cationic resin. After elution from the resin, 
the heparin is purified by precipitation upon additon of organic solvent, followed by filtration and 
drying (van der Meer, Kellenbach et al. 2017). The average molecular weight of full size, 
unfractionated heparin (UFH) obtained in this process is 16,000 Da, while the more recently 
developed low molecular weight heparin (LMWH) ranges from 3500-6000 Da (Liu and Linhardt 
2014). The LMWH is obtained by partial depolymerization of UFH, including nitrous acid 
treatment (Dalteparin), alkaline beta-elimination (Enoxaparin) and treatment with heparinase 
(Tinzaparin) (Linhardt and Gunay 1999). The newest addition to the heparin-type drugs is the 





The different sizes of the saccharide chains of UFH, LMWH, and fondaparinux 
contributes to their different pharmaceutical properties. For example, UFH is cleared through the 
liver and is considered safe to use with kidney-impaired patients, while the smaller molecular 
sizes of LMWH, and especially fondaprinux, promote clearance through the kidneys 
(Chandarajoti, Liu et al. 2016). UFH also displays a lower bioavailability due to greater binding 
to blood plasma proteins (Hemker, Al Dieri et al. 2019). The half-lives of the drugs are 
proprtional to their size, with the fondaparinux half-life at approximately 17 hours (Donat, Duret 
et al. 2002) while LMWH and UFH display half-lives of 2-6 hours and 0.5-1 hours, respectively 
(Pempe, Xu et al. 2012). The action of UFH can be rapidly reversed with the basic polypeptide 
protamine, while this is only partically effective for LMWH and not at all effective for 
fondaparinux (van Veen, Maclean et al. 2011). 
 
A major difference among the three types of heparin drugs is in their molecular 
mechanism of action. The anticoagulant activity of heparin is primarily a result of binding to the 
serine protease inhibitor antithrombin (AT) (Linhardt 2003). AT activated by heparin can inhibit 
both factor Xa and factor IIa, both of which are members of the coagulation cascade. Binding to 
a specific 3-O-sulfated pentasaccharide sequence in heparin induces a conformation change in 
AT that extends a reactive site loop in AT which occupies the active site of the coagulation 
protease. Inhibition of factor Xa only requires AT binding to the pentasaccharide sequence, 
while inhibition of thrombin requires the pentsaccharide sequence to be incorporated at the 
reducing end of an oligosaccharide with a minimum size of an 19-mer (Xu, Pempe et al. 2012).  
The pentasaccharide increases the rate of AT-inhibition of Xa over 150 times higher than for IIa. 
On the other hand, UFH shows preference for factor IIa, with a 7 times higher inhibition rate for 





Because thrombin directly controls formation of fibrin and has a central role in feedback 
regulation of the coagulation cascade, it is seen by some as an attractive drug target (WEITZ 
2007). UFH has a higher preference for thrombin than LMWH or fondaparinux.  It is also rapidly 
cleared from the blood (Alban 2008) and can be readily reversed with protamine (Cosmi 2015). 
Unfortunately, UFH also has a low bioavailability and a substantially higher probability of 
causing the potentially deadly side-effect heparin induced thrombocytopenia (HIT) (Arepally and 
Ortel 2010) Ideally, synthetic UFH could be developed with minimal unwanted side effects, but 
the anti-IIa activity characteristic of UFH requires a mnimum 19-mer oligosaccharide, making 
the synthesis highly difficult.  
 
Design of heparin mimetics with anti-IIa activity 
The structure of the ternary complex of factor IIa, antithrombin, and a 16-mer glucose-
based heparin mimetic implies a potentially simpler means to synthesize mimetics with anti-IIa 
activity. The structure exhibits a ‘bridge’ region within the glycan that does not make contact 
with either IIa or AT (Figure 3.1) ((Li, Johnson et al. 2004). Thus, rather than a contiguous 
oligosaccharide, a non-glycan linker could be positioned within the bridging region (Grootenhuis, 







Figure 3.1. Ternary complex of thrombin, AT, and the heparin mimetic SR123781 (Li, Johnson et 
al. 2004). The 16-mer mimetic is composed of repeated glucose residues (Petitou, Herault et al. 1999). 
Binding domains comprise the AT-binding pentasaccharide, and a highly suflated trisaccharide binding 
thrombin. A bridge region containing eight monosaccharides completes the scaffold. (PDB file 1TB6, 
prepared with PyMol).  
 
We hypothesized that heparin mimetics constructed from two chemoenzymatically 
synthesized oligosaccharides connected with a fliexible non-glycan linker could exhibit 
substantial anti-IIa activity. A similar strategy was employed in the past by linking 
dodecasaccharides obtained from size fractionated depolymerized heparin (Rong, Nordling et 
al. 1999). However, the component oligosaccharide were obtained by enzymatic digestion of 
naturally-occuring heparin and thus had a heterogenuous structure. For out method, we 
reasoned the two fragments could be conjugated using the copper catalyzed azide-alkyne 
cycloaddition (CuAAC). Based on the ternary complex structure, the AT binding 
pentasaccharide should be on the reducing side of the oligosaccharide chain, while the IIa 
domain should be positioned on the non-reducing end. To construct the AT-binding domains, 




position (GlcNAz) onto the non-reducing end of an oligosaccharide containing the AT-binding 
pentasaccaride sequence. The thrombin binding domain was synthesized starting with 
glucuronic acid with a β-glycosidic linkage to para-nitrophenol (GlcA-pNp) that had been 
modified to display a heptyne linker on its non-reducing end, allowing for connection of the two 
oligosaccharides while preserving their directionality (Figure 3.2). 
 
 
Figure 3.2 Oligosaccharide linkage strategy. Panel A shows the structure of oligosaccharides linked 
through the CuAAC formation of a triazole ring. The AT-binding domain is oriented on the reducing side, 
while the IIa-binding domain is on the non-reducing end, as shown in panel B.   
 
Although a certain size threshold is required for heparin to display anti-IIa activity, chains 
above this threshold tend to exhibit more potent anti-IIa activity in accordance with their size. 
This is explained by a model where AT binds to its high-affinity sequence in heparin, and 
subsequent binding to IIa is promoted by IIa translating on the exposed saccharide chain (Avci, 
Karst et al. 2003). Greater inhibition of IIa by longer saccharide chains has been observed in 
size-fractionated natural heparin (Bray, Lane et al. 1989), poly-glucose heparin mimetics 
(Petitou, Duchaussoy et al. 1998), and chemoenzymatically synthesized heparin (Xu, Pempe et 
al. 2012). To test the anti-IIa of the linked modular structures, and to look for a similar pattern of 
size-mediated anti-IIa activity, we synthesized a series of linked heparin mimetics consisting of 








Figure 3.3. CuAAC-linked factor IIa inhibitors synthesized for this study. 
 
Based on modeling of the linked structure (Figure 3.4), we estimated the linker will 
extend about two monosaccharides in the ternary complex. Therefore the ‘bridging’ region 
needed to be extended. This was done by adding unmodified GlcNAc and GlcA residues to the 
non-reducing side of AT-binding domains. For the 15- and 16-mer, one extra GlcA residue was 
added. For the 18-mer, a GlcA-GlcNAc-GlcA sequence was appended, while for the 20- and 24-
mer, a GlcA-GlcNAc-GlcA-GlcNAc-GlcA was added. The AT-binding sequence for the 16-mer 
was based on the bovine AT-binding sequence, which contains a GlcNAc6S on the non-






Figure 3.4. Linked structure superimposed into the 12-mer glycan from PDB structure 1TB6. Linker 
is shown with green carbons and purple carbohydrate residues. 12-mer SR123781 is shown in blue. The 
linker structure was manually into the glycan and energy of the entire chain was minimized. In this model, 
the linker occupies the length of two monosaccharide residues. (Schrödinger 2016, PyMol) 
 
For the II-a binding domain, it’s important to recognize the glycan SR123781 in PDB 
structure 1TB6 contains a highly sulfated IIa-binding trisaccharide with ten sulfates. Compared 
to AT, the interaction of IIa and heparin is more non-specific, based on electrostatic interactions 
(Sheehan and Sadler 1994). Therefore, binding of IIa to heparin can be enhanced by higher 
negative charge on the heparin chain (Petitou, Herault et al. 1999). This high density of sulfates 
is not present in naturally occuring heparin, so a longer thrombin-binding domain is required. To 
provide sufficient negatively charged monosaccharides for interaction with thrombin, each 
thrombin binding domain displayed a minimum of four sulfated carbohydrate residues. The IIa 













Synthesis and characterization 
 
 









   AT-
binding:    
   octa-1 GlcNAz-GlcA-GlcNAc6S-GlcA-GlcNS3S6S-IdoA2S-GlcNS6S-GlcA-pNp 2173.5 ± 0.3 2173.7 
   octa-2 GlcNAz-GlcA-GlcNS6S-GlcA-GlcNS6S3S-IdoA2S-GlcNS6S-GlcA-pNp 2211.8 ± 0.5 2211.7 
   deca-3 GlcNAz-GlcA-GlcNAc-GlcA-GlcNAc6S-GlcA-GlcNS3S6S-Ido2S-GlcNS6S-GlcA-pNp 2552.5 ± 0.6 2553.0 
   dodeca-4 GlcNAz-GlcA-[GlcNAc-GlcA]2-GlcNAc6S-GlcA-GlcNS3S6S-IdoA2S-GlcNS6S-GlcA-pNp 2932.0 ± 0.2 2932.4 
    
   IIa-binding:   
   hepta-6 GlcA-GlcNAc6S-GlcA-GlcNS3S6S-IdoA2S-GlcNS6S-GlcA-yne 2007.9 ± 0.5 2007.7 
   octa-7 GlcNS6S-GlcA-[GlcNS6S-IdoA2S]2-GlcNS6S-GlcA-yne 2366.8 ± 0.4 2367.0 
   dodeca-8 GlcNS6S-GlcA-[GlcNS6S-IdoA2S]4-GlcNS6S-GlcA-yne 3521.2 ± 0.6 3521.9 
    
Linked:    
   15-mer 
GlcA-GlcNAc6S-GlcA-GlcNS3S6S-IdoA2S-GlcNS6S-GlcA-[PPT]-GlcNAz-GlcA-GlcNAc6S-
GlcA-GlcNS3S6S-IdoA2S-GlcNS6S-GlcA-pNp 4181.3 ± 0.8 4181.4 




GlcNS6S3S-IdoA2S-GlcNS6S-GlcA-pNp 4580.0 ± 1.9 4578.7 




GlcNAc6S-GlcA-GlcNS3S6S-Ido2S-GlcNS6S-GlcA-pNp 4919.8 ± 0.8 4920.0 




GlcNAc6S-GlcA-GlcNS3S6S-IdoA2S-GlcNS6S-GlcA-pNp 5299.6 ± 1.7 5299.3 










Figure 3.5. Synthetic scheme for oligosaccharide components. All syntheses start with either a GlcA-
pNp or GlcA-derivatized with heptynoic acid linker. All compounds initially share a common synthetic 
path. They are first extended into an N-sulfated hexasaccharide, then an IdoA2S residue is installed. A 
GlcA is then added to yield a heptasaccharide. This heptasaccharide is destined to become either an AT-
binding domain or a IIa-binding domain. After 6- and 3-O-sulfation, the AT-binding domain is complete. 
This was extended into GlcNAz-labeled Octa-1, Octa-2, Deca-3, or Dodeca-4. Hepta-6 is also prepared 
along this route (note that hepta-6, although it contains an AT-binding domain, was used as the IIa-
binding domain in the 15-mer). To form the IIa-binding oligosaccharides, the heptasaccharide (IIa-binding 
path) is extended with multiple rounds of synthesis of the IdoA2S-GlcNS6S disaccharide to yield the 






Figure. 3.6. Mass spectrometry characterization of AT-binding component oligosaccharides. 






Figure. 3.7. Mass spectrometry characterization of AT-binding component oligosaccharides. 
Calculated (top) and observed (red, bottom) m/z values correspond to diferent charge states. 
 
Each linked structure was analyzed with NMR, ESI-MS, and HPLC. Because of limited 
amounts of material and the complexity of the compounds, only 1-D 1H-NMR was used to 
analyze the final linked structures (The NMR characterizations of the oligosaccharide 
components are shown in the appendix). For the linked compounds, the anomeric protons were 
identified in their 1-D 1H-NMR spectra . Also, for all linked structures, the aromatic region 
displays four doublets. One pair of doublets corresponds to to GlcA-pNp aromatic ring, the other 
corresponds to the linker phenyl ring. A singlet peak corresponding to the triazole proton is also 





Figure 3.8. 15-mer. 1H-NMR with anomeric protons annotated in the inset, and ESI-MS.  
 
 






Figure 3.10. 18-mer. 1H-NMR with anomeric protons annotated in the inset and ESI-MS. 
 
Figure 3.11. 20-mer. 1H-NMR with anomeric protons annotated in the inset and ESI-MS. 
 




Factor Xa and Factor IIa inhibition 
We tested both the anti-Xa and anti-IIa activity of the compounds. This was done with 
purified enzymes AT and IIa or Xa using a chromogenic substrate. In this assay the coagulation 
protease cleaves the chromogenic substrate which is a mimic of the natural protease substrate. 
The reaction rate can be correlated with the rate of increase in absorbance (at 405 nm) over 
time. The reaction rate at 100% is calculated from the control reaction where no inhibitor is 
added. Relative reaction rates for varying amounts of inhibitor are fit to a four parameter logistic 
curve in order to calculate IC50 values.  
Compound IIa IC50 (nM) Xa IC50 (nM) Xa:IIa 
Heparin (UFH) 0.51 ± 0.03 1.38 ± 0.07 2.7 ± 0.2 
24-mer 0.32 ± 0.01 1.04 ± 0.04 3.3 ± 0.2 
20-mer 0.73 ± 0.03 1.18 ± 0.06 1.6 ± 0.1 
18-mer 1.36 ± 0.09 1.34 ± 0.09 1.0 ± 0.1 
16-mer 25 ± 22 2.5 ± 0.1 0.1 ± 0.1 
15-mer Not detectable 2.3 ± 0.2 Not applicable 
Octa-1 Not applicable 2.7 ± 0.1 Not applicable 
Deca-3 Not applicable 1.12 ± 0.09 Not applicable 
Dodeca-4 Not applicable 1.34 ± 0.07 Not applicable 
 
Table 3.2. IC50 values for inhibition of IIa and Xa. Compounds Octa-1, Deca-3, and Dodeca-4 
correspond to the AT-binding domains for the linked compounds.  
 
For inhibition of factor Xa, only binding of AT to the pentasaccharide sequence is 
required. Therefore all compounds were expected to show similar anti-Xa activity, which is what 
was observed. As seen in Table 2, the IC50 values for factor Xa for all the linked compounds 
ranged from 1.0 to 2.5 nM. The anti-Xa IC50 values for the 18-, 20-, and 24-mer, and heparin all 
fell closely in the same range, between 1.0 and 1.4 nM, while the 15-mer and 16-mer had nearly 




the surface of AT and the GlcNAc-triazole-linker, which is positioned closer to the AT-binding 
pentasaccharide than for the other compounds. 
The inhibition of factor IIa showed a trend toward increasing IIa inhibition as chain length 
increased (Figure 3.13). The highest molecular weight linked compound, the 24-mer, exhibited 
greater IIa inhibition than UFH. For the three largest linked compounds, the 24-, 20-, and 18-
mers, IC50 values increased by a factor of approximately two for each. The 16-mer exhibited 
much weaker inhibition of IIa, and for the 15-mer, IIa inhibition was not detectable. 
 
 
Figure 3.13. Linked heparin mimetics inhibition of coagulation factors Xa and IIa. Panel A – 
inhibition of factor Xa, Panel B – inhibition of factor IIa. Error bars show one standard deviation from 
midpoint. Reaction rate at each concentration point represents rate of reaction determined by cleavage of 
a chromogenic substrate mimic S-2238. 
The chromogenic assay for inhibition of factor IIa appeared to show the linked 
compounds had anti-IIa activity comparable to UFH. To additionally verify this effect was indeed 
a result of the linear size of the linked compounds, we conducted the same factor IIa inhibition 
assay using a 1:1 molar mixture of each linked compounds component oligosaccharides. The 
compounds with significant anti-IIa activity were used (the 24-mer, 20-mer, and 18-mer).For 




and dodeca-8 (IIa-binding domain). These were mixed in a 1:1 molar ratio and assayed for 
factor IIa inhibition activity. Even at roughly one hundred times the anti-IIa IC50 for the linked 
compounds (120 nM), only a 10-20% reduction in IIa reaction rate was observed (Figure 3.14).  
 
Factor 3.14. Inhibition of factor IIa by non-linked component oligosaccharides. 1:1 molar equivalent 
mixtures of non-linked oligosaccharide components of 24-, 20-, and 18-mer exhibit negligible inhibition of 
factor IIa.  
Mixing the non-linked oligosaccharide components of 24-, 20-, and 18-mer did not lead 
to appreciable anti-IIa activity compared to the linked parent compounds, thus further confirming 
the anti-IIa inhibition was a result of scaffolding of AT and IIa by the linked structures. In order to 
further verify that the observed anti-IIa activity was a result of the scaffolding interaction 
between the heparin-mmetic, AT, and factor IIa, we repeated the chromogenic anti-IIa assay in 
the absence of antithrombin. If the observed inhibition of factor IIa is a result of them acting as a 
classical scaffold for the assembly of IIa and AT, the absence of AT should remove their effect 
on IIa. At the concentrations near those used with the linked heparin-mimetics used for the 
factor-IIa assay, the results appeared to be randomly scattered around 100% reaction rate for 





Figure 3.15. Inhibition of factor IIa in the absence of antithrombin. 
 
Thrombin Generation Assay 
The above assays were done in vitro with purified AT and factor Xa/IIa. In order to 
assess the effect of the compounds on the coagulation cascade, we employed the thrombin 
generation assay. Because thrombin catalyzes the formation of fibrin from fibrinogen, a 
measurement of thrombin generation through the coagulation cascade provides a readout of the 
overall anti-coagulant effect of a drug (Gray, Mulloy et al. 2008). This assay is carried out in 
human plasma with a fluorogenic thrombin substrate. Besides giving information on the 
anticoagulant effect of the linked compounds on the coagulation cascade, testing the 
compounds in the plasma milieu will also help rule out potential off-target binding or aggregation 
that would render the compounds ineffective drugs. The TGA begins with the initiation of clotting 
in plasma. The assay measures IIa generation by measuring the rate of fluorescence (Hemker 
and Kremers 2013). Because IIa is a central regulator of the coagulation cascade and has 
positive feedback on its own generation, its inhibition will cause a pronounced damper on the 
rate of fluorescence. Thus, compounds that inhibit thrombin will have a much more pronounced 
effect in the thrombin generation assay while inhibition of Xa only leads to a weaker response 





Figure 3.16. Thrombin generation assay for UFH, 24-mer, and 24-mer component 
oligosaccharides. Rate of fluorescence is proportional to thrombin generation. Curve is also shifted right 
under inhibition of thrombin generation. Linked 24-mer indicates potent inhibition of thrombin generation, 
with essentially no thrombin generation at 52.1 nM concentration, while UFH indicates traces of thrombin 
generation at 52.1 nM. Non-linked 24-mer components and the AT-binding component of 24-mer 
(Dodeca-4) are shown on bottom row.  
 
In the thrombin generation assay, the rate of fluorescence is proportional to thrombin 
generation. With increasing amounts of anticoagulant, the area under the curve will decrease as 
well as shift rightward as the coagulation cascade is slowed (Hemker and Kremers 2013). The 




inhibition of thrombin generation on par with UFH. On the other hand, the non-linked 
oligosaccharide components of the 24-mer showed weaker activity, with the combined non-
linked oligosaccharides and the single AT-binding domain exhibiting similar profiles, which is 
likely a result of the weaker effect of factor Xa inhibition on the coagulation cascade (Figure 
3.16) (Gray, Mulloy et al. 2008). In the in vitro anti-Xa assay, both the 24-mer and its isolated 
non-linked AT-binding domain dodeca-4 exhibited anti-Xa IC50s of 1.04 nM and 1.34 nM, 
respectively, which further confirms the potent thrombin generation inhibition of the full 24-mer is 
a result of its inhibition of IIa. When the results of the thrombin generation assay is compared for 
all linked compounds (Figure 3.17), a definite trend is seen, where the 24-mer exhibits most 
potent inhibition, and the 16-mer weakest. For the 15-mer, which was shown in the purified IIa 
assay to have very weak IIa inhibition, its thrombin generation inhibition is essentially the same 






Figure 3.17. Thrombin generation assay curves for UFH, all linked compounds, and AT-binding 
oligosaccharide dodeca-4. The curve decreases and shifts rightward with increasing anticoagulant. 
 
Active Clotting Time Assay 
To further test the anticoagulant activity of the compounds, we next moved to the active 
clotting time assay (ACT). The ACT is typically used in procedures that require high doses of 




carry high risks of bleeding and the ACT is a fast point-of-care test used to monitor 
anticoagulant activity. Because the ACT is done with whole blood, it provides the most accurate 
physiological reflection of anticoagulant levels among available anticoagulant assays (Horton 
and Augustin 2013). As with the thrombin generation assay, because of thrombin’s central role 
in feedback regulation of coagulation, inhibitors of thrombin exhibit the strongest response in the 
ACT. In the ACT, coagulation is initiated with celite and time to clotting is measured 
mechanically. Because the 24-mer exhibited strong signs of factor IIa inhibition using the 
thrombin generation assay and purified IIa assay, we chose it for the ACT. Likewise, we picked 
the 15-mer as a linked compound that had been shown to have poor anti-IIa activity. In 
agreement with previous assays of thrombin inhibition, the 24-mer appeared to show greater 
extension of clot time than for UFH, while the 15-mer exhibited weaker anticoagulation than 
UFH (Figure 3.18).  
 
Figure 3.18. Active clotting time (ACT) test. Addition of increasing amounts of anticoagulant leads to 
increased time for blood clotting. Clot time for 0 nM inhibitor is normalized to 1.0 for all compounds. Error 





A major advantage of UFH is its reversibility through the administration of protamine 
(Hirsh, O’Donnell et al. 2007). Protamine is a poly-lysine polypeptide that binds to the anionic 
heparin chains through electrostatic charge interactions. We assessed the protamine 
reversibility of the linked compounds using the factor Xa chromogenic assay. All compounds 
were added to a final concentration of 7.75 nM (approximately 5 times IC50), and protamine 
concentration was varied. UFH was, as expected, highly sensitive to protamine. Interestingly, of 
all linked structures, the 16-mer appeared to be most sensitive to protamine.  The 15-mer did 
not appear to show any sensitivity to protamine, and the 24-, 20-, and 18-mers showed partial 
sensitivity (Figure 3.19). 
 
Figure 3.19. Reversal of factor Xa inhibition by protamine sulfate. UFH or heparin-mimetics were 
added to a final concentration of about five times the IC50, and protamine sulfate concentration was 
varied. The 100% reaction rate was determined by measuring the rate of Xa cleavage of the chromogenic 
substrate without the presence of protamine or inhibitor. Error bars represent one standard deviation. 






 Many of the clinically important properties of UFH are a result of its molecular size. 
Compared to low molecular weight heparin and the pentasaccharide fondaparinux, UFH exhibits 
a rapid clearance, reliable reversal with protamine, and is amenable to the active clotting time 
point of care test (Hirsh, O’Donnell et al. 2007). The inhibition of thrombin by UFH leads to 
powerful inhibition of the coagulation cascade, which requires a minimum of a 19-mer. Yet the 
synthesis of even a heparin pentasaccharide has proven to be quite challenging (Petitou and 
van Boeckel 2004). The total synthesis of contiguous heparin oliogsaccharides with a size of 
approximately 20 saccharide residues would be highly difficult, especially for the libraries of 
varied structures required for structure activity studies. Faster, alternative means to the total 
synthesis approach of heparin is needed. 
Here we used the copper catalyzed azide-alkyne cycloaddition to link 
chemoenzymatically synthesized heparin oligosaccharides. This ‘click’ chemistry reaction is 
generalizable to a variety of oligosaccharides. Using this approach we synthesized a series of 
linked heparin mimetics ranging from a 24-mer to a 15-mer. These structures consisted of an 
AT-binding domain on the reducing end, and a thrombin-binding domain on the non-reducing 
side.  
These compounds all exhibited roughly similar factor Xa activity, as would be expected 
since only the presence of the AT-binding pentasaccharide is required for Xa inhibition (Linhardt 
2003). The anti-Xa IC50 values for the 15-mer and 16-mer were approximately twice that of the 
other linked compounds. This may be a result of the placement of the linker. On the 15-mer and 
the 16-mer, the AT-binding domain is an octasaccharide. Because the linker is attached on the 
acetyl group of the non-reducing terminal GlcNAz, this may result in steric clashing between the 




domain is at least a decasaccharide which would position the linker further away from the Xa 
protein.  
The anti-IIa activity of the series of linked compounds correlated with their size, with the 
minimum sized compound that still showed significant anti-IIa activity being the 16-mer. The 15-
mer appeared to be below the minimum size for effective IIa inhibition. If the linker region is 
considered to add two residues in length to each structure, then the 16-mer could be said to 
have a length close to that of a contiguous 18-mer. These results appear to correlate with 
previous work using contiguous chemoenzymatically synthesized IIa inhibitors (Xu, Pempe et al. 
2012). In that study, a contiguous 19-mer showed weak anti-IIa activity comparable to the linked 
18-mer or 16-mer used here. We were happy to see the linked 24-mer showed more potent 
inhibition of IIa than even UFH. This was not seen with a contiguous 21-mer in the previous 
work (Xu, Pempe et al. 2012). 
The thrombin generation assay measures anti-coagulant activity in plasma. Because 
thrombin (i.e., factor IIa) is the principle effector protein in the coagulation cascade, inhibitors of 
thrombin exhibit much stronger dampening of thrombin generation. Consistent with the results 
of the purified protein assay with factor IIa, the 24-mer again appeared to have a stronger anti-
coagulant effect then UFH. Likewise, the length of the compound was directly proportional to its 
effect on thrombin generation, with the 15-mer appearing to have the same effect as a 12-mer 
containing an AT-binding domain. This pattern was again observed in whole blood where the 
24-mer showed stronger anticoagulant activity than UFH, while the 15-mer was much weaker 
than UFH.  
The results for the reversal of anti-Xa activity by protamine were less straightforward 
than for the other assays. There was no clear trend relating protamine sensitivity to molecular 
size. Although the 24-mer has the largest size, it did not show the most sensitivity to protamine. 




explanation for this is that the 16-mer has the highest sulfation density of any of the linked 
compounds. With eighteen total sulfates in the 16-mer, it is the only linked compound with an 
average of more than one sulfate per saccharide. Because protamine interacts with heparin 
electrostatically, this could explain its higher sensitivity to protamine. The stark contrast between 
the 15-mer and the 16-mer in their protamine reversal is interesting. However, it has also been 
shown in previous work that small changes in sulfation can have significant effects of protamine 
reversibility (Xu, Cai et al. 2014). Overall, the experiments indicate the linked compounds show 



















CHAPTER 4: SUBSTRATE SPECIFICITY OF K5 LYASE1 
K5 lyase A (KflA) is a viral tailspike protein from the K5A bacteriophage that infects the 
K5 strain of Escherichia coli (Hänfling, Shashkov et al. 1996). The K5 strain of E. coli possesses 
a polysaccharide capsule that is composed of heparosan, a glycosaminoglycan with the   
repeating disaccharide unit: [-4)-GlcA-β(1,4)-GlcNAc-α(1-] (Roberts 1996, Leiman, Battisti et al. 
2007). This polysaccharide capsule is recognized by the K5A phage and allows for host 
specificity, but the capsule must be penetrated for the phage to access the entry receptor on the 
cell surface. To accomplish this, KflA molecules on the phage tailspike bind and depolymerize 
the heparosan capsule and expose the viral entry receptor (Clarke, Esumeh et al. 2000). KflA 
follows the general mechanism of the large class of polysaccharide degrading enzymes called 
polysaccharide lyases (Garron and Cygler 2010). It cleaves heparosan by catalyzing a β-
elimination reaction at C-4 of glucoronic acid (GlcA), which breaks the glycosidic bond and 
yields a Δ4,5 unsaturated GlcA at the nonreducing terminus of the oligosaccharide product 
(Clarke, Esumeh et al. 2000). Although it is believed to follow a catalytic mechanism like that of 
other polysaccharide lyases, the structure of KflA most  closely  resembles that  of  glycoside  
hydrolases  in  the GH90 family, many of which are also phage tailspike proteins serving an 
analogous function in viral entry (Garron and Cygler 2010). These tailspike proteins, including 
KflA, all feature homotrimeric parallel β-helix architecture (Barbirz, Müller et al. 2008, 
Thompson, Pourhossein et al. 2010). It has been proposed that the intensive structural similarity 
of the phage tailspike proteins indicates an evolutionary relationship in spite of their lack of  
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significant sequence homology (Jenkins, Mayans et al. 1998, Barbirz, Müller et al. 2008). 
The enzyme KflA and K5 strain of E. coli have been of interest in the field of heparin and 
heparan sulfate (HS) glycobiology, because the K5 capsule polysaccharide is structurally 
identical to the biosynthetic precursor of heparin and HS. Heparin and HS function in a wide 
variety of processes in mammals and have roles that include blood coagulation, cell proliferation 
and development (Linhardt 2003). During synthesis by the cell, heparosan is assembled by 
glycosyltransferases and enzymatically modified in several ways: deacetylation and subsequent 
N-sulfation of GlcNAc, epimerization of GlcA to iduronic acid (IdoA), sulfation of the 2-OH on 
GlcA or IdoA and sulfation of 6- and 3-OH groups on N-acetylglucosamine (GlcNAc) or N-
sulfated glucosamine (GlcNS) (Linhardt 2003). This results in a highly variable, heterogeneous 
pattern of sulfation and epimerization in the chain. The tendency of polysaccharide lyases to 
cleave these complex substrates in a predictable manner has made them important tools in 
glycosaminoglycan research (Michaud, Da Costa et al. 2003, Sasisekharan, Raman et al. 
2006). The bacterial polysaccharide lyases include three heparin lyases (heparinases I, II and 
III) that have been integral to many advances in the understanding of heparin and HS biology, 
such as the identification of the antithrombin-binding site on heparin that is responsible for its 
anticoagulant properties (Lindahl, Backstrom et al. 1979). More recently, KflA has been used to 
propose a structure for HS consisting of highly sulfated regions interspersed with unmodified 
domains possessing the heparosan-like structure and domains with inter- mediate levels of 
sulfation (Murphy, Merry et al. 2004). KflA has also been used to identify vascular endothelial 
growth factor- binding sites in HS (Robinson, Mulloy et al. 2006). Both of these experiments 
exploit the specificity of KflA for heparosan that has not been modified by sulfation or 
epimerization. The potential for further applications of KflA in heparin and HS research make it 




There were two primary goals in this study. The first originated with the revision of the 
amino acid sequence of KflA (GenBank accession number CAA71133.2) that accompanied the  
publication of  its  crystal structure in  2010 (Thompson, Pourhossein et al. 2010). In 2000, the 
protein sequence CAA71133.1 was published alongside a study that identified the gene for KflA 
within the K5 phage genome and described the expression of recombinant KflA (Clarke, 
Esumeh et al. 2000).  Figure  4.1  shows  a partial alignment of the two sequences of the 
regions with the most consecutive mismatches. There are a total of 42 mismatched amino acid 
residues between the two sequences. In the period after the first sequence was published, but 
before it was revised in 2010, a number of fundamental biochemical studies were done with 
KflA. It was not completely clear that the sequence was used for these studies, which included 
experiments on the specificity of KflA. Therefore, before beginning further experiments on the 
specificity of KflA, we wanted to be certain that the same protein sequence had been used 
throughout the earlier studies on KflA and that there was simply a mistake in the sequence data. 
Our second goal was to assess the substrate specificity of KflA  using synthetic  
oligosaccharide  substrates.  Products from treating the substrates with KflA were characterized 
by mass spectrometry. A similar strategy has been successfully employed by other groups on 
heparinases I and II (Ernst, Rhomberg et al. 1998, Rhomberg, Shriver et al. 1998). Previous 
studies on the specifi- city of KflA have focused on polymeric glycosaminoglycans and  have  
shown  that  KflA  does  not  degrade  chondroitin sulfate, heparin, hyaluronic acid, N-sulfo 
heparosan or chemically desulfated N-acetylated heparin (Murphy, Merry et al. 2004, Rek, 
Thompson et al. 2007). HS showed modest amounts of degradation by KflA, which was 
correlated with cleavage at regions possessing the heparosan-like structure (Murphy, Merry et 
al. 2004). Earlier work has also investigated the minimum size of sub- strates required for 
cleavage by KflA, and it was reported that heparosan decasaccharide was fully degraded, while 




al. 2004). The heparosan degrading activity of KflA was first observed in whole K5 phage 
particles,  where  it  was  reported to  cleave  the  substrate with  a random, endolytic mode of 
action (Hänfling, Shashkov et al. 1996). However, the cleavage of heparosan with K5 phage 
particles also gave larger-sized oligosaccharide products (decasaccharides to hexasaccharides) 
than the mixture of octasaccharides to disaccharides observed when heparosan is cleaved with 
the recombinant  KflA  enzyme (Hänfling, Shashkov et al. 1996, Murphy, Merry et al. 2004, 
Blundell, Roberts et al. 2009). The reason for this difference is not clear.  
Here, we have set to understand the specificity of KflA, especially with regard to isolated 
GlcNS residues, and the substrate size. Up to this time, KflA has not been studied using 
structurally homogeneous sulfated oligosaccharides, so we expect this approach should move 
toward a more consistent understanding of its specificity and insight into its mode of action. We 
synthesized a series of oligosaccharide substrates for KflA based on the structure of heparosan 
and established the effect of a single GlcNS   in   the   oligosaccharide   chain.   In   the   N-
sulfated octasaccharide (Octa-4) substrate, no cleavage was seen at the [GlcNS-GlcA] bond; 
however, in an N-trifluoroacetylated octasaccharide (Octa-3), the [N-trifluoroacetyl glucosamine 
(GlcNTFA)-GlcA] bond was cleaved. Additionally, Octa-4 was only cleaved on the reducing side 
of the GlcNS. We elongated the Octa-4 substrate at the nonreducing end one sugar residue at a 
time, which allowed the GlcNS to be retained in the same rela- tive position. When the substrate 
was extended to Deca-6, cleav- age was observed on both the nonreducing and reducing sides 
of the GlcNS residue. Our study advances the understanding of the substrate specificity of KflA, 








Sequence CAA71133.2 gives a soluble and active enzyme 
A recent paper in 2010 reports substantial changes in the amino acid sequence of KflA 
compared with the gene for KflA that was first identified in 2000 (Thompson, Pourhossein et al. 
2010). In the 10-year period between 2000 and 2010, a number of studies were done 
characterizing the biochemistry of KflA. To verify the sequence, we expressed and purified KflA 
protein based on the Genbank sequences for both CAA71133.1 (the sequence published in 
2000) and CAA71133.2 (the sequence published in 2010). Both sequences were expressed in 
E. coli as (His)6-tagged fusion proteins and purified on a nickel-Sepharose column. Only the 
sequence CAA71133.2 yielded a protein with measurable activity and gave a band near the 
56.3-kDa size as determined with sodium  dodecyl  sulfate  polyacrylamide  gel  electrophoresis 
(SDS-PAGE) (Figure 4.1). While the estimated molecular weight (70.9 kDa) is larger than the 
apparent value, a post-translational protease cleavage is speculated. It is believed that the C-
terminal end of KflA from Ser505  is autocatalytically cleaved to remove a 14.6-kDa  
autochaperone  fragment  from  the  initial  70.9-kDa protein (Thompson, Pourhossein et al. 
2010). To verify that the CAA771133.1 was being expressed, but in an insoluble form, we 
included a control where the CAA771133.1-containing vector was present but was not induced 
with isopropyl-β-D-thiogalactopyranoside. The 65-kDa band was only seen in the sample where 
expression was induced, but this band was not visible in the supernatant from the centrifugation 
step that followed cell lysis. The lack of solubility for CAA771133.1 could be indicative of the full 
amino acid se- quence that has not undergone the post-translational autocatalytic cleavage that 
removes a 14.6-kDa C-terminal fragment from the protein, yielding an insoluble form of protein. 
The C-terminal region from Ser505  contains 17 of the 42 total amino acid mis- matches, 
possibly destabilizing the autochaperone and autocatalytic function that has been proposed to 





Fig. 4.1. (A) There are a total of 42 mismatched amino acids in the two published sequences for KflA 
(CAA71133.1 from 2000 and CAA71133.2 from 2010). Shown here are 38 of the mismatches that are 
mostly concentrated in three rows of the alignment of the two sequences. (B) Expression of CAA71133.2 
gave soluble, active protein with the expected molecular mass (56.3 kDa theoretical for post-
translationally cleaved protein). 
N-sulfo heparosan and 6-O-sulfo heparosan are not substrates for KflA 
To verify that sequence CAA71133.2 encodes an active lyase, we evaluated the 
oligosaccharide products formed when heparosan   was   incubated with KflA.   The   elution 
profile   of KflA-degraded heparosan from a BioGel  P-10  column  is shown in Figure 4.2A. The 
absorbance at 232 nm, which corresponds to the Δ4,5  unsaturated glucuronic acid product of 
KflA cleavage (as depicted in Figure 4.2D), was used to monitor the presence of product in 
fractions. Electrospray ionization mass spectrometry (ESI-MS) confirmed the identity of the 
peaks that are labeled in Figure 4.2A. Both the elution profile and MS identities of the products 
were largely consistent with those published in earlier work by other groups, namely the 
products are mixtures of oligosaccharides ranging from di- to octasaccharides (Murphy, Merry et 





Fig. 4.2. Heparosan depolymerization by KflA gives a mixture of octasaccharides through disaccharides. 
These were identified by P-10 fractionation of the depolymerization products followed by scanning 
fractions at 232 nm and confirming peaks with ESI-MS. N-[35S]sulfo heparosan and 6-O-[35S]sulfo 
heparosan were treated with KflA or with vehicle. P-10 fractions show experimental and control samples 
elute in the same range and indicate that the enzyme was nonreactive with these polymers. 
 
Next we set out to assess whether N-sulfo heparosan or 6-O-sulfo heparosan could act 
as a substrate for KflA. Both substrates were 35S-radiolabeled. N-[35S]-sulfo heparosan and 6-
O-[35S]-sulfo heparosan were incubated with KflA overnight. After incubation, the reaction 




fraction were compared with the plot of a control consisting of the respective sulfated heparosan 
incubated without the enzyme. As  illustrated in  Figure 2B  and  C,  N-sulfo heparosan and 6-O-
sulfo heparosan treated with KflA were eluted the same as those of undigested polysaccharide 
substrates, suggesting that neither  served  as  a  substrate  for  KflA.  With respect  to N-
sulfated heparosan, our result here confirmed that of others, which showed N-sulfated 
heparosan is not cleaved (Murphy, Merry et al. 2004). The effect of 6-O-sulfation on KflA 
substrate had not been assessed previously. 
 
Table 4.1. Summary of KflA oligosaccharide substrates 
 
Minimum size of the KflA substrate 
To determine the minimum length of substrate required for cleavage by KflA, we exposed the 
lyase to hexa- and octasac- charides. Both oligosaccharide substrates were isolated from KflA-
degraded heparosan, and their structures were confirmed by ESI-MS as shown in Table 4.I. The 
digestion reaction was carried out by incubating Δ4,5 hexasaccharide (Hexa-1) and Δ4,5  
octasaccharide (Octa-2) with KflA, and the products were analyzed by the BioGel P-2 column 
coupled with ESI-MS (Figure 4.3). Octa-2 was almost fully degraded to yield di-, tetra- and 
hexasaccharides (Figure 4.3A and B). For example, the analysis of fraction 51 revealed a strong 
signal at the m/z value of 1136.6, along with 1158.5 m/z and 568.1 m/z. Taking these values as 
the [M−H]−, [M−H+Na]− and [M−2H]2−  fragments, respectively, these indicate an 
oligosaccharide product with a molecular weight of 1137.7 ± 0.4 (Figure 4.3B). This measure- 




structure of ΔUA-GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc. The  exposure  of  Hexa-1  to KflA  
resulted  in  mostly  (undigested) hexasaccharide along with  only  a  small  amount  of  
disaccharide, suggesting that Hexa-1 was resistant to digestion (data not shown). Our data 
suggest that octasaccharide is the minimum size for KflA digestion, which is consistent with the 
previous publication (Murphy, Merry et al. 2004). Based on this conclusion, our subsequent 
studies were focused on using substrates at least as large as octasaccharides to further 
investigate the substrate specificity of KflA. 
 
Fig. 4.3. (A) The possible products from KflA catalyzed degradation of the Δ4,5 octasaccharide, Octa-2. 
The theoretical molecular weights of each of the fragments are also shown. (B) BioGel P-2 fraction 






Effect of a single N-sulfation on cleavage of octasaccharide substrate 
We determined the contribution of N-sulfation to the susceptibility to  degradation  by  
KflA  using  a  series  of  synthetic oligosaccharides. To this end, a total of four 
oligosaccharides, ranging  from  octa-  to  decasaccharides,  were  synthesized (Octa-3  to  
Deca-6,  Table  4.I). The results from ESI-MS analysis confirmed the identity of the anticipated 
products (Table 4.2–4.4). To first determine the sites cleaved by KflA for substrate lacking N-
sulfation, we began with the octasaccharide shown in Figure 4.4A. In Octa-3, the third sugar 
residue from the non- reducing end is a GlcNTFA residue. The GlcNTFA residue is a bioisostere 
of GlcNAc, and it can be readily converted to a GlcNS via chemoenzymatic methods (Masuko, 
Bera et al. 2012). In addition, a para-nitrophenol  ( pNP) group is attached to the reducing end 
of the substrate, which is used as a means for ultra violet detection (monitored at 310 nm). The 
substrates were incubated with KflA, and the products were analyzed by BioGel  P-2  and  ESI-
MS.  The  plots  of  A310   vs.  fraction number illustrate the relative amounts of the pNP-tagged 
species and are shown in Figure 4.5. The summary of  these  analyses is  shown  in  Tables  
4.2–4.4. For Octa-3 substrate, degradation with KflA yielded four products (Figure  4.4A),  
indicative of  two  sets  of  cleavages  by  KflA (Table 4.2). One cleavage occurred at position 2, 
yielding pentasaccharide(a) and trisaccharide(b); another cleavage occurred at position 3, 
yielding trisaccharide(c) and pentasaccharide(d).  Our  data  also  confirmed  that  neither  the  
pNP group nor the TFA substitution on the glucosamine residue affects the susceptibility to 







Fig. 4.5. Plots of A310 vs. fraction number from the BioGel P-2 separation of the products from KflA 
cleavage of the four oligosaccharides in Fig. 4.4. The A310 corresponds to the absorbance peak of the 
pNP tag. The respective substrates in the plots are (A) Octa-3 (B) Octa-4 (C) Nona-5 (D) Deca-6. 
 
After establishing the pattern of cleavage for Octa-3, the TFA group was exchanged with 
an N-sulfate to give Octa-4. The digestion of Octa-4 with KflA only yielded two products (Figure 
4B), suggesting that only a single cleavage occurred on this substrate. Analysis with BioGel P-2 
and ESI-MS revealed that the cleavage site is located at position 2. The lack of products 
corresponding to cleavage at position 3 demonstrates that KflA is unable to cleave the linkage 





Tables 4.2-4.4.KfiA cleavage of oligosaccharides  
 
The effect  of  the  GlcNS  residue  on  the  KflA  cleavage pattern was further 
investigated by extending the length of the oligosaccharide substrates. The addition of one GlcA 
to the nonreducing end of Octa-4 resulted in Nona-5. The digestion pattern of Nona-5 to KflA is 
very similar to that observed for Octa-4 (Figure 4.4B and Table 4.3), namely only single 
cleavage was observed. The addition of another GlcNAc residue to Nona-5 yielded Deca-6. 
Incubation of Deca-6 with KflA resulted in a more complex mixture of products. The results from 
product analysis revealed that KflA cleaved on three sites in Deca-6 (Figure 4.4C): the first 
scenario is to cleave at position 5 to yield a nonasaccharide( g) and a monosaccharide product. 




 The second scenario is to cleave at position 4, yielding trisaccharide(h) and 
hexasaccharide(i). Both trisaccharide(h) and hexasaccharide(i) were observed by ESI-MS 
(Table 4.4). The third scenario is to cleave at position 2, resulting in trisaccharide(b) and 
hexasaccharide( j). In addition, hexasaccharide( j) was further degraded to tetrasaccharide(k). 
All these oligosaccharide products were observed by ESI-MS (Table 4.4). As expected, no 
cleavage at position 3 was found. 
Discussion 
Polysaccharide lyases are valuable tools for glycosaminoglycan research, and KflA itself 
has already been shown to be useful in the study of the structure of HS. Understanding its 
specificity toward single sulfations of the heparosan substrate could further extend the 
applications of KflA in heparin and HS   analysis.  Here, we   demonstrate  that   only   Genbank 
sequence CAA71133.2 produced a soluble and active KflA enzyme. The degradation of 
polymeric heparosan with CAA71133.2 gave a product profile similar to that seen using KflA 
before the sequence was corrected in 2010 (Murphy, Merry et al. 2004). Through comparing our 
results with those published by other groups, it seems likely that CAA71133.1 was never used in 
the previous studies and was reported as the result of errors in gene sequencing. However, 
there were anomalies in the work that first identified and sequenced the KflA gene that led us to 
question, which protein sequence was used for this study. Their SDS–PAGE result shows a 
band at approximately 67 kDa, which is much closer to the 70.9 kDa expected for the full 
peptide than 56.3 kDa for the post-translationally cleaved product (Clarke, Esumeh et al. 2000). 
Our SDS–PAGE experiment gave a band positioned near 56 kDa, which corresponds to the 
removal of the 14.6-kDa segment. The crystal structure of KflA verifies that this segment is 
excised in the mature protein (Thompson, Pourhossein et al. 2010). It is unclear why 
CAA71133.1 failed to give a soluble product. There are 17 of the 42 total mismatched amino 




Ser505    to  the C-terminus), which could disrupt the autochaperone and auto- catalytic  
functions  associated  with  this  region (Thompson, Pourhossein et al. 2010). 
In this article, we used defined oligosaccharides ranging from oligosaccharides to 
decasaccharides to show that KflA is sensitive to the presence of GlcNS residues. We have 
also shown that the glycosidic bond consisting of [GlcNS-GlcA] is resistant to degradation by 
KflA. Replacing the GlcNS residue with the GlcNAc bioisostere, GlcNTFA renders this bond 
susceptible to cleavage. Although the oligosaccharides were not fully digested,  the  extent  of  
cleavage  can  be  enhanced  by adding more KflA enzyme or prolonging the incubation time 
(Rek, Thompson et al. 2007). 
Our data show that heparosan substrates smaller than an octasaccharide are no longer 
susceptible to degradation. At the same time, incubation of KflA with polymeric heparosan 
results in mostly disaccharide products (Figure 2). Using a model of random endolytic cleavage 
by KflA (Hänfling, Shashkov et al. 1996), one would expect the majority of the products to be 
larger than hexasaccharides. A model of processive cleavage by polymeric heparosan KflA 
could explain the predominance of tetrasaccharides and disaccharides that is observed. Indeed, 
a processive cleavage model for the K1-5 phage has been proposed (Leiman, Battisti et al. 
2007). 
It is apparent that the size of the substrate has effects on the cleavage pattern of KflA. 
All three of the synthetic substrates have a common cleavage site at position 2. However, when 
the substrate is extended to Deca-6, there is a dramatic change in the cleavage pattern by KflA 
(Figure 4.4). For instance, position 4 is not susceptible for cleavage in Nona-5, but is cleaved in 
Deca-6. The basis for this is unclear based on our understanding of the crystal structure of KflA. 
This work does show that KflA is able to recognize and cleave domains containing isolated 




of HS domains with low-sulfate content. However, the variable cleavage patterns of KflA due to 
























CHAPTER 5: MATERIALS AND METHODS 
Oligosaccharide backbone synthesis 
Glucuronic acid p-nitrophenol (GlcA-pnp) (Sigma) was added to 25 mM tris buffer, pH 
7.2, at a concentration of 1.2 mM. This was mixed with 1.2 equivalents of UDP-GlcA  and 0.1 
mg/L pasteurella multocida heparosan synthase 2 (PMHS2) and incubated overnight at 30 °C. 
The UDP-sugar and enzyme contained NaCl, for a final concentration of 50-150 mM.  HPLC 
(polyamine column) was used to insure that the reaction had run to ≥ 90% completion. After 
completion, the reaction mixture was acidified to pH 2.0 with 30% trifluoroacetic acid, 
centrifuged (11,000 x g for 30 min.), filtered (0.45 micron), and purified on a C18 reverse phase 
chromatography column. The column ran at 2.0 mL/min with 0.1% trifluoroacetic acid in both 
buffers, at a gradient of 0 to 100% methanol in 2 hours. Buffer was evaporated in a 
centrifuge/vacuum at room temperature overnight. The process is identical for addition of 
GlcNAc to yield a trisaccharide, using UDP-GlcNAc in place of UDP-GlcA (PMHS2 is 
bifunctional). These two steps are alternated to yield the heparosan backbone. Elongation steps 
performed after the substrate contains sulfation are the same, except a Q-sepharose DEAE 
column was used for purification, as described below for the sulfation enzymatic steps. 
 
Oligosaccharide sulfation/epimerization 
The epimerization and 2-O-sulfation of iduronic acid are carried out simultaneously. 
Substrate (0.13 mM), 5’-phosphoadenosine-sulfate (PAPS) was added to final concentration 0.2 




heparan sulfate 2-O-sulfotransferase and heparan sulfate Hsepi, and incubated at 37 C 
overnight. Reaction progress monitored by HPLC, and pushed to completion by the same 
methods described for the backbone synthesis. The reaction mixture pH was adjusted to 5.0 
with 30% acetic acid in water, centrifuged at 12,000 x g for 30 min., filtered (0.45 micron), and 
loaded onto Q-sepharose. Separation buffer A consisted of 25 mM sodium acetate, pH 5.0, and 
buffer B was 25 mM sodium acetate, pH 5.0 with 2 M sodium chloride. Gradient used pure 
buffer A to 80% buffer B over a three hour period. The fractions are dialyzed in pure water using 
a 1000 Da MW cutoff membrane in 5000 mL of double distilled water, changing the water every 
3 hours for a total of 9 hours. 
To carry out the enzymatic synthesis of GlcNS from GlcNTFA, first the trifluoroacetate 
group was hydrolyzed by incubating the substrate at 20 mg/mL in 0.1 lithium hydroxide on ice 
for 2 hours. The solution was neutralized with 1 M HCl. The N-sulfation and 6-O-sulfation 
reactions are exactly analogous only differing in the enzyme used. The substrate was diluted to 
0.3 mM in 50 mM MES, pH 7.0. The sulfo- donor, PAPS, was added at 0.5 mM per each group 
requiring sulfation and the enzyme, either HS N-sulfotransferase (without the deacetylase 
domain) or 6-O-sulfotransferase were added to 0.1 mg/L, and allowed to react overnight at 37 
C. Purification was the same as for the 2-O-sulfation/epimerization reaction. 
 
N-azidoacetyl-glucosamine (GlcNAz) synthesis 
Glucosamine hydrochloride was added to water at 10 mg/mL. azidoacetic acid (3 
equivalents) was added, and the pH was adjusted to 5.0 with dropwise addition of aqueous 1M 
HCl/NaOH.  Then 1.5 equivalents (based on glucosamine) of 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) (Sigma) was added. The mixture was vortexed. After 




hours a sample was evaluated on the mass spectrometer. The mixture was poured over a 
column of dowex 50 x 4 (1mL volume of wet resin for 10 mg of glucosamine starting material) to 
remove EDC, and the pH was neutralized. The material was used without further purification.  
 
UDP-GlcNAz synthesis 
N-azidoacetyl-glucosamine (Fisher) was diluted to 10 mM in 20 mM tris pH 7.0 buffer 
with 100 mM NaCl. To this was added 12 mM ATP and 0.1 mg/L of N-acetylhexosamine 1-
kinase (NaHK). After incubation at 37 C for 12-18 hours, the reaction was centrifuged (tabletop) 
at 10,000 rpm for 30 minutes. The supernatant was kept and to this was added 12 mM UTP and 
0.2 mg/L of GlcNAc 1-P-uridyltransferase (GlmU). After overnight incubation at 37 C the 
reaction mixture was placed in boiling water for 1 minute, or until cloudy. This was centrifuged at 
11,000 x g for 30 minutes and the resulting mixture was used for subsequent steps in the 
chemoenzymatic elongation. The synthesis of UDP-GlcNAc and UDP-GlcNTFA were performed 
analogously, using N-acetylglucosamine or N-trifluoroacetylglucosamine, respectively, as the 
starting material. 
 
Synthesis of glucuronic acid p-(hept-6-ynamido)-phenol (GlcA-yne) 
The synthesis of the GlcA-phenyl-heptyne linker glycoconjugate begins with GlcA-pnp. 
In a round bottom flask affixed with a reflux condenser, 100 mg of GlcA-pnp (sigma) was added 
to 10 mL of methanol, 100 mg of 10% Pd/C, and 40 mg of ammonium formate was added last. 
The mixture was heated in a 45 C water bath which was allowed to cool to room temperature 
over the period of 4 hours. Mass spectrometry was used to monitor reduction of the nitro group. 
The completed reaction mixture was filtered after addition of 50-100 mg of celite, the solvent 




absorbance at 290 nm were collected after verification of the reduced product with mass 
spectrometry. The fractions were again dried. The dried material was added to water (10 
mg/mL) and 15 molar equivalents of hept-6-ynoic acid (sigma) were added. The pH was 
adjusted to 5.0 with dropwise 1 M NaOH/HCl. The carbodiimide EDC was added at 1.5 molar 
equivalents, vortexed and allowed to react at room temperature for 4 hours. Reaction progress 
was monitored by HPLC, and the completed reaction mixture was purified on C18 reverse 
phase chromatography column with water/methanol (both containing 0.1 % TFA) using a 0-
100% gradient of methanol over 2 hours. Fractions containing product as indicated by UV 
absorbance at 240/260 nm (with a higher 240 nm absorbance than 260) were confirmed as the 
GlcA-aniline-heptynoic acid conjugate with mass spectrometry and dried. 
 
Copper catalyzed azide-alkyne cycloaddition 
The two reactants displaying either the azide or alkyne were added to 100 mM 
potassium phosphate buffered water (pH 7.0) at 200 mM for one reactant, and 175 mM for the 
other. The water used for the reaction, including to make the copper sulfate and ascorbic acid, 
had been kept under vacuum for at least 3 days to reduce the amount of dissolved oxygen. A 1 
M solution of copper sulfate was prepared, and 5 molar equivalents of the Cu ligand THPTA 
(with respect to copper) were added to this. To the Copper sulfate/THPTA solution was added 5 
molar equivalents of sodium ascorbate (with respect to copper). After briefly vortexing the three 
reagents the mixture was quickly added to the reactants after briefly incubating them on ice for 
30 seconds to insure formation of Cu(I) and chelation of this by THPTA. The amount of the 
reagent mixture used was so that the ration of Cu to the 200 mM reactant was 1.5:1. The 
reaction was capped and shaken at 30 C for 3 hours. After the three hours an additional aliquot 
of sodium ascorbate was added. Progress was monitored with HPLC. The completed reaction 




mM sodium acetate pH 5.0) and buffer B (20 mM sodium acetate pH 5.0, 2 M NaCl). After 
loading to the column, the column was washed for 1 hour with 10% buffer B, followed by a  3 
hour gradient of 0-80% buffer B. The purity of the collected fractions was checked with HPLC, 
pooled, and dialyzed (5000 mL, 3 hours, changed ddH2O three times).  
 
Factor IIa and Xa assays 
Solutions of factors IIa and Xa (Chromogenix and Sigma, respectively) were prepared at 
100 nM and 80 nM, respectively, in PBS with 1 mg/mL BSA. The antithrombin stock was 
prepared at 400 nM in the same PBS/BSA buffer. Stock solutions of the IIa and Xa substrates, 
S-2238 and S-2765 (Sigma), respectively, were prepared in PBS at 1.5 nM for S-2238 and 1.3 
nM for S-2765. A series of inhibitor samples, or the positive control, heparin, were prepared in 
PBS at 8.33 times the desired final concentration. In a 96 well plate, 70 µL of the AT stock was 
added to 15µof sample and incubated at 25 C with mixing on a plate shaker for 2 minutes. A 10 
µL volume of either IIa or Xa was added, and further incubated for 4 minutes with continuous 
mixing. A volume of 30 µL of substrate was added and mixed for 10 seconds, followed by 
monitoring at 405 nm for 3 minutes, for a total of 15 data points. The absorbance was plotted vs. 
time, visually inspected to insure linearity, and the reaction rate was taken from a linear 
regression of this plot. Each series of samples contained three wells where PBS was used in 
place of sample. The reaction rates for these were averaged and taken as the 100% rate, and 
the rates of the other reactions were scaled proportionally. Final plots are based on the average 
of at least three assays. Standard deviation of these assays is shown on the plots. The IC50 
values were calculated with Sigmaplot 12.5, fitting to a four parameter logistic curve, with error 





Thrombin generation assay 
Heparin or heparin mimetic samples were dissolved in 80 µL various concentrations and 
arrayed in a 96 well microplate. Human plasma was added and activated by the addition of 15 
mM calcium chloride for 3 minutes. The fluorogenic thrombin substrate Z-Gly-Gly-Arg-AMC was 
present at a concentration of 416 uM. Thrombin generation was initiated by the addition of 4 pM 
recombinant tissue factor 1-263 (Haematologic Technologies Inc) lipidated with a 4 uM 1:4 
mixture of 1-palmitoyl-2-oleoyl-phosphatidylserine and 1-palmitoyl-2-oleoyl-phosphatidylcholine. 
Fluorescence data was collect with a Biotek Synergy H1M plate reader. Fluorescence units 
were converted to thrombin concentration using a thrombin standard curve.  
 
Protamine reversibility assay 
In a 96 well plate, a solution of antithrombin was prepared at 400 nM in PBS containing 
1 mg/mL BSA. 100 µL of antithrombin stock was mixed with 23 µL of Xa individual heparin or 
heparin mimetic inhibitor prepared to give a final concentration of 7.75 nM. After incubating 3 
minutes with mixing at room temperature, protamine (Sigma) was added in 30 µL PBS at 
varying concentrations. After mixing 5 min. at room temperature, 15 µL of factor Xa (Sigma) was 
added. After an additional incubation at 4 minutes, the 50 µL of the Xa chromogenic substrate 
S-2765 (Sigma) was added, at 1.5 nM concentration. Reaction rates were calculated as for the 
standard factor Xa assay above.  
 
Activated clotting time assay 
Fresh blood samples of 1.0 mL were placed in a glass tube containing a magnetic bead 




rotated and clotting time is taken as time for the coagulated blood to induce rotation of the bead. 
Heparin and synthetic oligosaccharides were dissolved in PBS and added to blood for 1 min. 
prior to the assay. Ratios are normalized by comparison to the clotting time for blood treated 
only with PBS. Samples are performed in triplicate.  
 
NMR Analysis 
Samples (2.0-20.0 mg) were dialyzed and lyophilized. Protons were exchanged to 
deuterium by treatment with deuterium oxide (0.5 mL) followed by lyophilization. This process 
was repeated twice more, and samples were dissolved in 0.4 m of 99.994% deuterium oxide 
(Sigma) and transferred to a 5.0 mm OD NMR tube. Samples were analyzed on a Varian Inova 
500 MHz spectrometer with VnmrJ 2.2 software. 1-D 1H-NMR samples were analyzed with 64 
scans. 2-D 1H-NMR experiments were analyzed over 1-6 hours. Data for 1-D 12C-NMR and 




Electropray ionization mass spectrometry was done on a Thermo LCQ Deca in negative 
ionization mode. Samples were first exhaustively dialyzed in 10 mM ammonium bicarbonate. To 
prepare for injection, 10 µL of dialyzed sample was added to 200 µL of 10 mM ammonium 
bicarbonate. Spray voltage was set at 3.5 kV with a capillary temperature of 275 °C. The sample 
was injected by a syringe pump (Hamilton, NV) at 10 μL/min. Scans were averaged over 1 min 





Expression and purification of (His)6-tagged KflA 
The cDNA for KflA with NCBI GenBank accession numbers CAA71133.2 and 
CAA71133.1 were purchased from GenScript optimized for expression in E. coli, in plasmid 
pUC57. The same protocol was used for both CAA71133.2 and CAA71133.1. The primers 5′-
AGTACATATGATGGCAAAACTGACCAAACCG-3′ and 5′- 
AGGAGGATCCTTACTTCGGCAGGGCGGCCAG-3′ were synthesized (Invitrogen, NY). The 
restriction sites for Nde1 and BamH1, respectively, are underlined. Amplification via polymerase 
chain reaction consisted of 5 min at 95°C, then 25 cycles of the following: 30 s at 94°C, 30 s at 
52°C, 2.5 min at 68°C and a final period of 10 min at 68°C. The vector pET-15b and the cDNA 
were treated with Nde1 and BamH1 and ligated using the manufacturer’s protocol from the DNA 
rapid ligation kit (Roche, IN). E. coli DH5α (Invitrogen) was transformed with the ligation product, 
colonies from the transformation were shaken overnight in 3 mL Luria-Bertani (LB) media with 
carbenicillin (50 μg/mL for all LB media), and plasmid was extracted following the 
manufacturer’s protocol with the QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany). 
Samples of purified plasmid were treated successively with Nde1 and BamH1 and resolved on 
5% agarose gel to identify correctly ligated plasmids for sequencing (Genome Analysis Core 
Facility, University of North Carolina, CA). Plasmids (KflA in pET-15b) were transformed into 
BL21* E. coli (Invitrogen), and colonies were shaken in 3 mL LB media overnight (37°C), added 
to 100 mL LB media. and grown to A600 between 0.6 and 0.8 at 37°C, then cooled to 22°C and 
induced with isopropyl-β-D-thiogalactopyranoside (20 mM). The induced cells were shaken at 
22°C for 18 h and harvested by centrifugation (4000 × g, 12 min, 5°C). The pellet was 
suspended in ice cold buffer A (25 mM Tris–HCl, 500 mM NaCl, 40 mM imidazole, pH 8.5) and 
lysed with 3 × 30 s rounds of sonication (Branson, 45% duty cycle, power output 9), followed by 
centrifugation (15,000 × g, 30 min, 5°C). Supernatant was filtered (Millipore, 45 μm) and loaded 




0.8 × 4 cm, 0.5 mL/min). The column was washed with 75 mL buffer A and eluted with 1 mL 
buffer B (25 mM Tris–HCl, 500 mM NaCl, 40 mM imidazole, pH 8.5). The quantity of protein was 
estimated by A280, with 0.72 for sequence CAA71133.2 and 0.14 for CAA71133.1. Each eluent 
was tested for activity by adding 1 μL eluent to 3 μg of heparosan in 100 μL (Tris–HCl 25 mM, 
pH 8.5) and monitoring A232 and A280, with only CAA71133.2 showing significant (42%) 
increase in A232 over a 1-min period. Analyzed with 12% SDS–PAGE, eluent from protein 
CAA71133.2 ran at purity judged to be ≥90%, while no significant band was visible for eluent 
from sequence CAA71133.1. To test CAA71133.1 cells for the expression of insoluble protein, 
approximately 10 μL of pellet from the postlysis centrifugation of CAA71133.1 was added to 20 
μL water and 20 μL Laemelli buffer (5% β-mercaptoethanol), then boiled for 10 min to give a 
strong band at 65 kDa. Postlysis supernatant from CAA71133.1 was also used for. Finally, a 
100 μL sample of cells for CAA71133.1 taken directly after induction and incubation, harvested 
by tabletop centrifuge (5300 × g, 3min), decanted, suspended in 20 μL water and 20 μL Laemlli 
buffer (5% β-mercaptoethanol) and boiled for 10 min prior to 12% SDS– PAGE. 
 
Expression and purification of sulfotransferases and glycosyltransferases 
The synthesis of the N-sulfated and N-trifluoroacetylated oligosaccharides and sulfated 
heparosan required the enzymes N-sulfotransferase (NST), 6-O-sulfotransferase isoforms 1 and 
3 (6-OST-1, 6-OST-3), N-acetylglucosaminyltransferase (KfiA) and Pasteurella multocida 
heparosan synthase (pmHS2). The expression and purification of these enzymes has been 
described before (Chen et al. 2005, 2007). Briefly, the enzymes were expressed in E. coli as 
fusion proteins and purified accordingly, with NST tagged to a glutathione S-transferase and 
purified on a glutathione sepharose column (GE Healthcare), while 6-OST-1 and 6-OST-3 were 




Healthcare). Both KfiA and pmHS2 were expressed as (His)6 -tag fusions and purified on a 
nickel sepharose column (GE Healthcare). 
 
Heparosan incubation with KflA 
A solution of 5 mg/mL heparosan (molecular weight 30 kDa; Volpi 2004) was incubated 
with 9.0 μg of KflA in a total volume of 1 mL (25 mM HCl, pH 8.5) for 2 h at 37°C. The method 
used for the production of heparosan is described in section “Synthesis of heparosan”. The 
crude reaction mixture was mixed with 1 μL 0.5% phenol red and separated on a BioGel P-10 
column (BioRad, 0.75 × 200 cm) with an elution buffer containing 20 mM Tris–HCl and 1 mM 
NaCl (pH 7.5) at a flow rate of 3 mL/h. The absorbance of each fraction was measured at 232 
nm. The absorbance vs. fraction number plot shown in Figure 2 was constructed, and the three 
fractions with the highest absorbance for each of the four prominent peaks were pooled. Prior to 
analysis with mass spectrometry, these were either desalted by dialysis or BioGel P-2. The 
pooled fractions corresponding to the peak eluting last were assumed to be disaccharide. We 
desalted a 0.5-mL sample of these pooled fractions (with 1 μL 0.5% phenol red) with BioGel P-2 
(Biorad) in 0.1 M ammonium bicarbonate with a flow rate of 3 mL/h. The other pooled fractions 
from the P-10 separation were dialyzed against 20 mM ammonium bicarbonate using molecular 




Oligosaccharides were analyzed using both polyamine (Waters) and DEAE-NPR 
(Tosohaas) HPLC columns. For DEAE chromatography, elution conditions consisted of a 0-1 M 




rate of 0.5 mL/min. Elution conditions for the polyamine column consisted of a 0-1 M gradient of 
potassium phosphate over 40 minutes at a flow rate of 0.5 mL/min. UV absorbance was 
monitored at 310 nm for pNp labeled compounds, and at 240 nm for compounds where the pNp 
was modified with the heptyne linker.  
 
Synthesis of GlcNTFA and PAPS 
A chemoenzymatic method was used to synthesize GlcNTFA (Liu et al. 2010; Zhou et al. 
2011). The starting material GlcNH2 1-phosphate was reacted with S-ethyl trifluorothioacetate 
to give GlcNTFA 1-phosphate, which was condensed with uridine diphosphate with 
glucosamine-1-phosphate acetyltransferase/ N-acetylglucosamine-1-phosphate 
uridyltransferase (GlmU). GlmU is expressed in E. coli and purified with a nickel sepharose 
column. The sulfotranferase co-factor PAPS is also synthesized by a chemoenzymatic method, 
starting from adenosine triphosphate (ATP) (Zhou et al. 2011). In a one pot reaction, ATP is 
mixed with organic sulfate and is phosphorylated at the 3′ position by adenosine 5′-
phosphosulfate (APS) kinase, while ATP sulfurylase hydrolytically cleaves pyrophosphate and 
replaces it with sulfate to give PAPS. The reaction is carried out in the presence of 
pyrophosphatase to drive the reaction toward product. PAPS is purified from the reaction 
mixture using a DEAE column. The three enzymes used are expressed in E. coli as (His)6-








CONCLUSIONS AND FUTURE WORK 
 Over nearly a century of use, the natural product heparin has proven extremely resistant 
to synthetic attempts, leaving patients and clinicians to deal with a sub-optimal, heterogeneous, 
animal-sourced drug.  Likewise, the search for other heparan sulfate based drugs is hampered 
by difficulty obtaining defined structures to unravel HS-protein binding. The chemoenzymatic 
synthesis of heparin pioneered by Jian Liu’s lab has tilted the balance in this regard, providing a 
path for the synthesis of a variety of homogeneous, tailor-made heparin and HS 
oligosaccharides. However many of the properties of heparin and HS arise from fragments 
ranging from approximately 15-25 saccharides in length. Indeed, naturally occurring heparin and 
HS can range from 20 to 200 disaccharides in size. As the size of oligosaccharides increases, 
steps in the synthetic process - like separation of products from starting material - become much 
harder. Characterization with NMR also becomes more difficult. A modular method for linking 
the oligosaccharides could amplify the reach of chemoenzymatic synthesis even further.  
Here we have presented a method for using the copper catalyzed azide-alkyne 
cycloaddition to link chemoenzymatically synthesized oligosaccharides. We showed that linked 
oligosaccharides can recapitulate the anti-IIa activity characteristic of natural unfractionated 
heparin. In other words, at least in the case of the heparin-catalyzed inhibition of factor IIa by 
AT, these compounds can carry out the scaffolding function characteristic of heparin and HS. In 
the future, this method could be well suited for the rapid synthesis of a combinatorial library of 
linked HS mimetics for use in a microarray format.  
Because the linking of the glycans is done with the CuAAC click reaction, a bio-
orthogonal reaction well-suited to aqueous conditions, this method does not have to be only 
limited to straightforward synthesis of oligosaccharides. For example, a mixture of azide/alkyne 
functionalized oligosaccharides could be incubated with cells (or proteins) and click-linked in 




templating interactions with other macromolecules. We also describe a method for biotinylation 
of oligosaccharides in this paper – this could be a way of retrieving the oligosaccharides. It 
would also be fairly straightforward to substitute a cyclooctyne for the terminal alkyne, allowing 
for copper-free click chemistry that could potentially be used in vivo to block binding to AT or IIa 
and reverse anticoagulant activity. Finally, these compounds also could be used for the 
construction of well-defined neo-proteoglycans by clicking to proteins or peptides engineered to 
display at complementary functional group, or clicked to azide/alkyne functionalized sugars that 
had been metabolically incorporated into cells.  
Our work on the enzyme K5 lyase has pinned down ambiguity on its sequence found in 
previous literature, and shown it to be a highly selective enzyme. The heparinase enzymes have 
been integral tools in the analysis of heparin and HS for many decades, usually being used to 
cleave the GAG chains into disaccharides. As a member of the class of viral tailspike proteins, 
K5 lyase is also a highly thermo-stable enzyme. The structural stability and substrate specificity 
of K5 lyase could make it a promising target for directed evolution for the tailor-made cleavage 
of specific HS motifs, a technology which is not currently available. In fact, viral tailspike proteins 
have been touted as a rich source of novel carbohydrate-binding proteins {Barbirz, 2009 #288}. 
Here we have described our work on both the analysis and construction of HS glycans. 
Hopefully, the results in this thesis can assist in the effort of unraveling the complex biology of 
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